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I  Foreword
We are proud to present the 24th General Report of Activities of the European Monitoring 
Centre for Drugs and Drug Addiction (EMCDDA), which provides an overview of the 
agency’s achievements in 2018.
This was a year in which the value that the agency brings to its stakeholders and key 
partners was further confirmed. The external evaluation of the EMCDDA, which was carried 
out by the European Commission (EC) and presented to the EMCDDA Management Board 
in December 2018, concluded that the agency is performing very well, delivers excellent 
outputs and has a high reputation at both European and international levels. 
The EMCDDA will closely follow up on the set of recommendations outlined in the final 
report of the EC’s evaluation. This will guide the future activities of the EMCDDA at a time 
when, more than ever, the agency needs to remain policy relevant and structurally fit to 
respond to any new requirements from its stakeholders. 
Policy and practice relevance were at the core of our work throughout the year. The 
EMCDDA’s annual overview of the European drug situation, the 2018 European Drug 
Report package, was launched in Brussels in June in the presence of the EU Commissioner 
for Migration, Home Affairs and Citizenship, Dimitris Avramopoulos. In 2018, 30 Country 
Drug Reports and more than 40 other outputs were released, including, for the first time, 
a report on the medical use of cannabis: Medical use of cannabis and cannabinoids: 
questions and answers for policymaking. 
The agency’s role in coordinating the EU Early Warning System on new psychoactive 
substances was also strengthened in 2018 as a result of the application (on 23 November) 
of a new legal framework. This framework provides the EMCDDA with increased 
responsibilities and new formal partnerships with other EU agencies, and it amends its 
Founding Regulation (recast). 
In terms of our work with partners, 2018 was particularly rich as regards outputs, as 2018 
saw the launch of seven joint publications with EU agencies or international organisations.  
However, our core partners remain the Member States, in particular the Reitox national 
focal points (NFPs), which are the EMCDDA’s main data providers. The year 2018 was the 
first year of implementation of the Reitox Development Framework, which was adopted 
by the heads of the NFPs in 2017, and much of the agency’s efforts were focused on 
supporting the NFPs in this. 
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Another key development in our work with partners was the signing of a grant agreement 
between the EC and the EMCDDA to implement, from January 2019, a new technical 
cooperation project for European Neighbourhood Policy partner countries. Entitled ‘EU4 
Monitoring Drugs’, this will be the largest technical cooperation project carried out so far 
by the EMCDDA. It provides an important opportunity to support the EU in its work with 
priority third countries regarding improving the responses of these countries to drug threats. 
It also offers the opportunity to enhance the EU’s capacity for drug strategic analysis and 
response. 
Internally, the organisational transformation that was initiated with the adoption, in 2016, of 
the EMCDDA Strategy 2025 continued in 2018. Key steps were made towards the adoption 
of a work culture that is more project management oriented and, overall, increasingly agile.   
We would like to express our gratitude to the Management Board and the Scientific 
Committee for their ongoing support and guidance, to the Reitox NFPs and all their staff for 
their valuable contribution to the work of the EMCDDA and to all the staff of the agency for 
the progress achieved collectively in 2018.
Laura d’Arrigo 
Chair of the EMCDDA Management Board 
Alexis Goosdeel 
Director of the EMCDDA
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EU4MD EU4 Monitoring Drugs
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Euro-DEN Plus European Drug Emergencies Network
EUPC European Universal Prevention Curriculum
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EWA UNODC Early Warning System
EWS EU Early Warning System 
FDCS Federal Drug Control Service of Russia
GPS General Population Survey
HCIN Heads of Communication and Information Network
HCV hepatitis C virus
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HIPP WHO Health in Prisons Programme 
HIV human immunodeficiency virus
HNT Healthy Nightlife Toolbox
IAS Internal Audit Service of the European Commission
ICF Internal Control Framework
ICT information and communication technology
ICTAC Heads of Information and Communication Technology
INHSU International Network on Hepatitis in Substance Users
IPA instrument for pre-accession assistance
IPA6 technical cooperation project for IPA beneficiary countries
ISAJE International Society of Addiction Journal Editors
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IT information technology
ICS Internal Control Standards 
ICT information and communication technology
JHA Justice and Home Affairs Council 
KI key epidemiological indicator
KPI key performance indicator
LIBE Committee on Civil Liberties, Justice and Home Affairs
MEP Member of the European Parliament
M-Health mobile-health
MILDECA Mission interministérielle de lutte contre les drogues et les conduites addictives
MIS management information system
MoU Memorandum of Understanding
NAPO Network of Agencies Procurement Officers 
NEWS Early Warning System at national level
NFP national focal point
NPS new psychoactive substances
OAP operational action plan
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OSI open source information
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PCC potential candidate country
PD Programming Document
PDN Performance Development Network
PDU problem drug use
PhV pharmacovigilance
PM2 Project Management Squared
POD perspectives on drugs
PWID people who inject drugs
RDF Reitox Network Development Framework
RA Risk Assessment 
RAR Risk Assessment Reports
SCORE Sewage analysis CORe group — Europe 
SDG UN Sustainable Development Goal
SLA Service Level Agreement
SMART UNODC Global Synthetics Monitoring: Analyses, Reporting and Trends programme
TAIEX Technical Assistance and Information Exchange
TDI treatment demand indicator
TEDI Trans-European Drug Information
THB trafficking in human beings
THC tetrahydrocannabinol
UNODC United Nations Office on Drugs and Crime
UPC Universal Prevention Curriculum
UPC-Adapt UPC adapted to European needs and standards
WHO World Health Organization
Xchange online registry of evidence-based prevention programmes 
I
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 CHAPTER 1
 Executive summary
This report presents the implementation of the activities of the 
European Monitoring Centre for Drugs and Drug Addiction’s 
(EMCDDA’s) work programme for 2018, the first year of the 
multi-annual Programming Document (PD) 2018-20. 
I  EMCDDA publications
The most tangible results of the agency’s work are its 
publications, some of which are produced in cooperation with 
partners. In 2018, 45 scientific and corporate publications, 
in addition to 30 Country Drug Reports, were released by the 
EMCDDA. 
The flagship publication of 2018, the European Drug Report: 
Trends and Developments (EDR) and its accompanying 
information package, was launched in Brussels on 7 June. 
During the entire year, the number of unique downloads of the 
EDR (of the 2017 EDR until June and of the 2018 EDR from 
June onwards) was close to 100 000, which equates to almost 
one download every five minutes. 
In December, responding to a growing interest in the topic, 
the EMCDDA published its first report on the medical use 
of cannabis: Medical use of cannabis and cannabinoids: 
questions and answers for policymaking. In May, the EMCDDA 
also released its first analysis on monitoring drug-related 
homicide in Europe. Another innovative output was the 
EMCDDA Paper on mobile-health (m-health) applications for 
responding to drug use and the associated harm, which was 
released in December. 
Examples of other resources include topic overviews and 
updates on the environmental prevention of drug use, viral 
hepatitis policies in Europe, preventing drug overdose in 
Europe, new psychoactive substances (NPS) and the drug 
markets of captagon and cocaine. These were complemented 
by updated web topic pages on harm reduction, prevention, 
prisons and treatment. 
In addition to the legal outputs produced together with 
Europol as part of the implementation of the Council Decision 
2005/387/JHA on the information exchange, risk assessment 
and control of NPS, joint publications were also launched 
with the European Centre for Disease Prevention and Control 
(ECDC), namely two public health guidance documents on 
reducing communicable diseases in prison; with Europol, on 
the implementation of the revised supply indicators in the 
Member States, Norway and Turkey; with the Canadian Centre 
on Substance Use and Addiction, on cannabis and driving; and 
with the Cooperation Programme between Latin America and 
the European Union on Drugs Policies (COPOLAD), exploring 
new and emerging drug trends and developments in the 
Community of Latin American and Caribbean States (CELAC) 
countries based on the trendspotter methodology. 
Twenty-six scientific articles or book chapters authored or 
co-authored by EMCDDA staff were also published during the 
year, enhancing the agency’s scientific reputation.
I Services to policy and practice
The EMCDDA also provided services to its customers (i.e. 
the primary beneficiaries of the agency’s work: policymakers 
within the EU institutions — the European Parliament (EP), the 
Council of the EU and the European Commission (EC) — and 
the EU Member States, and practitioners in the drugs field) 
by: contributing to major EU drug policy documents; providing 
direct input or technical support to EU institutions (e.g. through 
briefing notes, presentations or interventions on emerging, 
high-interest drug issues or on activities with third countries); 
and participating actively in key drug policy and practice events 
held during the year. EMCDDA staff attended more than 60 
core policy and institutional events and overall contributed to 
around 300 drug-related scientific, policy and practice events 
(see Annex 5 for a full list of events attended by EMCDDA 
staff). 
Throughout the year, the EMCDDA also maintained 
communication with the Member States. The Director paid 
high-level institutional visits to five Member States and 
EMCDDA staff visited seven countries to support the national 
launches of the 2018 EDR. Further country visits were 
General Report of Activities 2018 Chapter 1 I Executive summary
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carried out at the invitation of national authorities to support 
different drug initiatives, such as a joint mission with ECDC 
to Luxembourg to review the observed increase in reported 
HIV cases among people who inject drugs (PWID) and to 
propose key actions, and the mission to Estonia to support the 
evaluation of Estonia’s drug prevention policy. 
Furthermore, the EMCDDA’s cannabis policy news service 
continued to provide regular alerts to its policy audience, and 
its audience doubled in 2018.  
I Best practice, training and capacity  building
The EMCDDA disseminated best practice, held training 
sessions and undertook capacity-building activities to share 
knowledge in 2018. 
In 2018, the EMCDDA’s Best practice portal (BPP) increased 
its multilingual reach, as parts of it became available in 
eight languages. An expert meeting on the implementation 
of evidence-based interventions on drugs took place and 
the ninth annual conference of the European Society for 
Prevention Research (EUSPR) was co-organised by the 
EMCDDA in Lisbon. Eleven new programmes, on crime and 
delinquency, were added to the online registry of evidence-
based prevention programmes (Xchange). 
The main EMCDDA vehicle for implementing training and 
capacity building for drug monitoring in Member States and 
partner third countries remained the Reitox Academies. During 
the year, 306 professionals were trained as part of the seven 
academies organised or supported by the EMCDDA, as well as 
through other activities supporting best practice provided by 
the agency upon the request of national authorities. 
Another training event that took place in 2018 was the sixth 
European Drugs Summer School, ‘Illicit drugs in Europe: 
demand, supply and public policies’, which was organised 
in Lisbon in partnership with ISCTE — University Institute of 
Lisbon (ISCTE-IUL). A record number of students took part 
(53); they had diverse backgrounds and originated from 25 
countries across the world. 
The EMCDDA also enhanced its contribution to the European 
training programme for law enforcement professionals 
implemented by the EU Agency for Law Enforcement Training 
(CEPOL). In 2018, as part of the tasks assigned to it within 
the operational action plans of the EU Policy Cycle on serious 
and organised international crime of the Council of the EU’s 
Standing Committee on Operational Cooperation and Internal 
Security (COSI), the EMCDDA contributed to the training of 
some 200 law enforcement professionals.
I Digital communication
As an information agency, the EMCDDA closely follows the 
developments in the fast-moving communication field. The 
EMCDDA website is the favoured vehicle for disseminating 
knowledge, with almost 1.4 million visitors registered in 2018, 
an almost 30 % increase compared with 2017. In addition, 
videos published by the EMCDDA on YouTube received around 
270 000 views during the year (compared with around  
190 000 views in 2017). 
At issue 100, Drugnet Europe was retired as a print and PDF 
publication and, in January 2018, it re-emerged in a new 
monthly digital news round-up format, transforming the way in 
which the EMCDDA gathers and reports news (i.e. into a digital 
service with more timely content). In 2018, 12 editions were 
launched and promoted online and via social media.
Furthermore, 46 digital campaigns were launched, with almost 
65 000 individual emails sent to subscribers. 
In 2018, 11 news releases and 51 news items were produced 
and news and events were better integrated in the EMCDDA 
website to reflect the agency’s activities. In addition, a total 
of 272 requests from the media were received and answered 
during the year. 
I New psychoactive substances and  emerging trends
In 2018, the EMCDDA continued to play a leading role in 
ensuring the continuous and robust implementation of the 
EU Early Warning System (EWS) on NPS. Until 23 November, 
this was carried out under the terms of Council Decision 
2005/387/JHA on the information exchange, risk assessment 
and control of NPS, after which the new legal framework (1) on 
NPS started being applied. 
(1) This new legal framework comprises: Regulation (EU) 2017/2101 of the 
European Parliament and of the Council of 15 November 2017 amending 
Regulation (EC) No 1920/2006 as regards information exchange on, and an early 
warning system and risk assessment procedure for, new psychoactive substances; 
and Directive (EU) 2017/2103 of the European Parliament and of the Council of 15 
November 2017 amending Council Framework Decision 2004/757/JHA in order 
to include new psychoactive substances in the definition of ‘drug’ and repealing 
Council Decision 2005/387/JHA.
General Report of Activities 2018 Chapter 1 I Executive summary
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The EWS was formally notified for the first time of 55 NPS 
during the year, bringing the total number of NPS currently 
monitored to around 730. 
Furthermore, the EMCDDA’s Extended Scientific Committee 
carried out risk assessments of two substances and the 
associated risk assessment reports were subsequently 
submitted to EU institutions, as stipulated by the above-
mentioned Council Decision, and published. Seven more risk 
assessment reports and two joint reports, all produced in 2017, 
were published in the EMCDDA layout in 2018.
Following the proposals of the EC, based on the two 
risk assessment reports submitted by the EMCDDA, in 
2018 the Council decided that ADB-CHMINACA and 
CUMYL-4CN-BINACA, as well as cyclopropylfentanyl and 
methoxyacetylfentanyl, should be subject to control measures 
at the EU level. This is the ultimate EU policy response to 
the NPS phenomenon and it shows that the agency has had 
significant input into EU policymaking. 
In addition to implementing the EWS, one of the EMCDDA’s 
key tasks in 2018 was to monitor new trends in the drug field. 
A trendspotter study, ‘Recent changes in Europe’s cocaine 
and crack market’, was carried out and its results were 
disseminated via a Rapid Communication. In December, the 
EMCDDA also published the Trendspotter manual: a handbook 
for the rapid assessment of emerging drug-related trends.
In 2018, the EMCDDA continued its collaboration with the 
Sewage Analysis CORe group Europe (SCORE). The latest 
findings were released in March as an updated Perspectives 
on Drugs publication: Wastewater analysis and drugs — a 
European multi-city study. 
Another new tool that was developed to help in the rapid 
reporting of new trends was the European Web Survey on 
Drugs, run with a number of Reitox national focal points 
(NFPs); this tool has now reached more than 50 000 
participants. In addition, the EMCDDA continued its support 
for innovative methods for better monitoring of new trends, 
including the analysis of syringe residues and pill testing.
I Core monitoring
In December, a comprehensive triennial review of the 
implementation of the EMCDDA key epidemiological indicators 
in the 30 reporting countries (i.e. the 28 EU Member States, 
Norway and Turkey) was conducted and presented to the 
Management Board. The assessment describes the progress 
made since the previous review (2015) and will inform work 
priorities in this area for the following three-year period  
(2019-21).
During the year, the EMCDDA continued to work closely with 
the principal investigators of the European School Survey 
Project on Alcohol and Other Drugs (ESPAD) to make use 
of the current survey results and to coordinate the activities 
necessary for the next round of ESPAD planned for 2019, 
including by providing support for national data collections in 
11 countries (EU Member States and third countries).
In May, the EMCDDA launched a three-year initiative with 
the purpose of promoting hepatitis C testing among PWID 
in drug treatment settings. The initiative represents both an 
operationalisation of a central EMCDDA public health priority 
and the implementation of a dynamic intervention model 
presented in Health and social response to drug problems: a 
European guide, a key EMCDDA resource which was released 
in 2017.
In the area of drug supply, focus continued to be placed on 
improving the quality and coverage of data collected in the 
Member States. A report was released jointly by the EMCDDA 
and Europol providing an overview of the key findings from 
the implementation of the revised drug supply indicators. 
Significant work was also carried out on the preparation of the 
third EMCDDA-Europol EU Drug Markets Report  
(for publication in 2019). 
I Working in partnership
In fulfilling its tasks, the agency relies on a large number 
of partners and, in particular, the Reitox NFPs. They play a 
critical role in providing national data from the 30 countries 
that report to the EMCDDA. In 2018, the EMCDDA supported 
the implementation by the NFPs of the Reitox Development 
Framework (RDF), which was adopted by the heads of the 
NFPs in 2017. The RDF will contribute to enhancing the 
visibility, the usefulness and ultimately the sustainability of the 
NFPs at the national level and of the NFPs as a network at the 
European level. 
In performing its work and achieving its objectives, the 
EMCDDA also relies on its other EU and international partners. 
At the institutional level, three new working arrangements were 
concluded, namely with Europol, ECDC and the European 
Medicines Agency (EMA), with a view to implementing the new 
NPS legislation. Two more similar working arrangements were 
prepared with the European Chemicals Agency (ECHA) and the 
European Food Safety Authority (EFSA) for signing in February 
2019.
In 2018, the EMCDDA chaired the EU Agencies’ Network on 
Scientific Advice (EU-ANSA). The focus of EU-ANSA’s work in 
2018 was on consolidating and completing ongoing activities 
in areas such as communicating scientific uncertainty and 
General Report of Activities 2018 Chapter 1 I Executive summary
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continuing work on the engagement of EU agencies with the 
EU research knowledge cycle and research clusters.
In terms of cooperation with third countries and international 
organisations and support for EU-funded projects, work was 
guided by the EMCDDA International Cooperation Framework, 
which was adopted by the Management Board in December 
2017. 
In this area, the agency continued to cooperate with 
enlargement countries and implemented the Instrument for 
Pre-accession Assistance (IPA) projects. To that end, the IPA 6 
project — which started in 2017 with the objective of further 
building the capacity for drug monitoring in six candidate 
and potential candidate countries (Albania, Bosnia and 
Herzegovina, Kosovo (2), Montenegro, North Macedonia and 
Serbia) — was successfully carried out. One of its key results 
for the year was the first-ever review of the operationality of 
the national drug observatory and the national early warning 
system on NPS in both Serbia and Montenegro, which was 
carried out in June. The project also launched the first-ever 
national general population survey (GPS) on drugs in Bosnia 
and Herzegovina and the results are expected in early 2019.
Finally, in March, the EMCDDA submitted a technical proposal 
to the EC for a new technical cooperation project for European 
Neighbourhood Policy (ENP) partner countries, entitled 
‘EU4 Monitoring Drugs’, to be financed by the European 
Neighbourhood Instrument (ENI). The grant agreement 
between the EC and the EMCDDA was signed in December 
2018 and the project started on 1 January 2019.
I Corporate developments
In 2018, the EMCDDA consolidated the organisational 
measures that were initiated in the previous year, with a view 
to ensuring the successful implementation of the EMCDDA 
Strategy 2025. 
A top priority in this area was to support the fourth external 
evaluation of the EMCDDA, which was carried out during the 
year by the EC. The final report of the external contractor, 
which was presented by the EC at the Management Board 
meeting in December 2018, contained some very positive 
results for the EMCDDA. According to the report, the agency 
is performing very well, delivers excellent outputs and has a 
high reputation at the European and international levels. The 
Commission report, which presents the main conclusions of 
the evaluation, was prepared by the EC and adopted on 14 
May 2019. 
During the year, the agency performed well both operationally 
and financially. This was confirmed by the high level of 
implementation of the 2018 Work Programme, as well as 
by the outstanding performance achieved by the EMCDDA 
in terms of budget execution, with 99.98 % of commitment 
appropriations executed. (2) This designation is without prejudice to positions on status, and is in line with 
UNSCR 1244/99 and the ICJ Opinion on the Kosovo declaration of independence. 
It applies to all mentions of Kosovo in this report and its annexes.
2
General Report of Activities 2018 Chapter 2 I Core business: monitoring  and reporting on the drugs problem
17 / 87
 CHAPTER 2
  Core business: monitoring  
and reporting on the drugs problem
I Communicating evidence and knowledge  exchange (Key area 1) 
The ultimate purpose of the work performed by the EMCDDA 
is to inform sound decisions in the field of drugs at the levels 
of the EU and its Member States. The results of the EMCDDA’s 
data collection, monitoring and analysis process provide 
policymakers and professionals from across the EU with the 
evidence they need to tackle the drug situation effectively. 
This evidence is communicated by the EMCDDA through 
various means, depending on the needs of its customers. In 
2018, a customer needs project was initiated. The aim of this 
project is to develop a framework through which the agency 
can carry out an assessment of customer needs in a more 
systematic way. It is at the heart of the agency’s customer-
centric approach set out in the EMCDDA Strategy 2025.
The agency’s most important means of communication are the 
outputs ― both products and services ― that it provides to its 
customers (see Figure 1). These outputs are complemented 
by a range of knowledge-exchange activities, which include 
the dissemination of best practice, as well as capacity-building 
and training initiatives. 
I Products
In 2018, the EMCDDA launched 45 scientific and corporate 
publications and 30 Country Drug Reports (3). In addition, 
EMCDDA staff authored or co-authored 26 scientific articles or 
book chapters, most of which have been published as open-
access publications.
The 2018 European Drug Report package
On 7 June, the EMCDDA presented its annual analysis  
of the drug problem in Europe, the EDR package (see  
Figure 2). The EDR is an interactive and interlinked annual 
update on the latest trends in drug supply and drug use,  
and on the associated health and social responses in Europe. 
Included in the package were a Trends and Developments 
report and the Statistical Bulletin.
Available in print and online in 24 languages, this multilingual, 
multimedia resource offers easy access to evidence-based 
information on drugs for the 28 EU Member States, Norway 
and Turkey. 
The report was launched at the EC in Brussels by Dimitris 
Avramopoulos, the European Commissioner for Migration, 
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Home Affairs and Citizenship, and by Alexis Goosdeel, the 
EMCDDA Director. Speaking at the press conference, the 
Commissioner warned: ‘The drug problem remains an 
important threat to both the health and the security of citizens 
and especially for our youth. Such a longstanding threat can 
only be tackled if we all work together — across Europe and 
with our international partners.’ 
The Trends and Developments report was downloaded once 
every five minutes in 2018 (i.e. 97 286 unique downloads) (4).
The 2018 EDR package was complemented by 30 Country 
Drug Reports, which presented summaries of the national 
drug situations in the 28 EU Member States, Norway and 
Turkey. Developed by the EMCDDA in cooperation with the 
Reitox NFPs, these graphic-rich reports cover drug use and 
FIgURE 2. European Drug Report package 2018
Press conference launch of the EDR on 7 June in Brussels. Dimitris 
Avramopoulos, European Commissioner for Migration, Home Affairs and 
Citizenship; Alexis Goosdeel, EMCDDA Director 
© European Union, 2019
public health problems, drug policy and responses, and drug 
supply. 
The Statistical Bulletin completed the picture by providing 
access to the quantitative data used by the EMCDDA for 
reporting on the drug situation.
The following products were also published on the day of the 
2018 EDR launch: 
  Fentanils and synthetic cannabinoids: driving greater 
complexity into the drug situation — an update from the 
EU Early Warning System (Rapid Communication);
  New psychoactive substances in prison (Rapid 
Communication);
  updates on Drug consumption rooms: an overview 
of provision and evidence (also available in French, 
German, Portuguese and Spanish) and on The misuse of 
benzodiazepines among high-risk opioid users in Europe 
(Perspectives on Drugs).
In addition, a motion graphic, two news releases in 24 
languages (a taster news release and a highlights news 
release), a special edition of the newsletter Drugnet Europe 
(issue 106) and a promotional brochure were produced by the 
agency to mark the launch of the EDR. 
The report was also launched in Bulgaria, Cyprus, Czechia, 
Hungary, Norway, Poland, Portugal and Romania.
Threat assessment reports
In 2018, the EMCDDA published several outputs related to 
the implementation of Council Decision 2005/387/JHA on 
the information exchange, risk assessment and control of (4) This figure includes 2017 report until 6 June and the 2018 report as of 7 June, 
the date of its launch.
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NPS (see Key area 2). Two EMCDDA-Europol joint reports on 
NPS and nine risk assessment reports were published in the 
EMCDDA layout. 
Topic overviews and updates on important drug-related 
issues 
Over the course of 2018, the EMCDDA also released various 
papers, technical reports and manuals on topics relevant to 
policymakers and practitioners.
Cannabis: controversies and challenges
In 2018, the EMCDDA began publishing a new series of papers 
entitled ‘Cannabis: controversies and challenges’ (see  
Figure 3). This series seeks to explore, in an objective and 
neutral manner, some of the complex issues that exist in 
this area. Each report will address a different aspect of this 
dynamic and complex policy area.
What is the evidence base for the medical use of cannabis 
and cannabinoids? What is the difference between cannabis 
preparations and medicinal products and why is this 
important? How is this issue regulated in the EU? These and 
other questions are explored in a report that was released 
in December in response to the growing interest in this 
topic, with an increasing number of European countries 
developing policies and best practice in this area (Medical use 
of cannabis and cannabinoids: questions and answers for 
policymaking — Rapid Communication).
With cannabis use and policy evolving internationally, drug-
impaired driving has become an increasingly relevant policy 
issue. The EMCDDA released a joint briefing with the Canadian 
Centre on Substance Use and Addiction entitled Cannabis and 
driving: questions and answers for policymaking. This briefing 
aims to provide those interested in policy developments in 
the field of cannabis with a brief overview of the current 
knowledge and the latest developments in the area. The 
briefing is also available in French, German, Portuguese and 
Spanish.
Harm related to drug supply 
Since 2013, the EMCDDA has been working on improving 
its framework for monitoring the supply side of the drugs 
problem to reflect the changing nature of drug markets and 
their wider harm and impact (see Key area 3). In December, 
the EMCDDA released a joint publication with Europol that 
provides a summary of the key findings from the assessment 
of the progress of the EU Member States, Norway and Turkey 
in implementing the revised drug supply indicators, which 
were developed by the EMCDDA and Europol in line with the 
Council conclusions of November 2013.
The effects of drugs and drug markets reach beyond those 
who are directly exposed to drugs and suffer ill effects in terms 
of health or social problems. Drugs and drug markets are of 
serious concern to the overall security situation in Europe 
and they deeply affect communities at large, as certain drug 
markets can be associated with acts of violence. In May, the 
EMCDDA released its first analysis on monitoring drug-related 
homicide in Europe. This first snapshot provides practitioners 
and policymakers with an overview of the current state of the 
art on this topic (see Key area 3).
Drug markets
In October, the EMCDDA Paper Captagon: understanding 
today's illicit market was published. It addresses several 
policy-relevant questions: What is captagon? Where is it used 
and produced? Can it be linked to terrorist attacks in Europe? 
The report provides an overview of what is currently known 
about the captagon phenomenon, with the aim of assisting 
those working in the illicit drugs field who may need to respond 
to the issue.
The latest changes in Europe’s cocaine market are explored 
in a report published in December (see Figure 4). This report 
was published following an analysis in the 2018 EDR that 
highlighted an increase in the availability of high-purity cocaine 
in Europe, a shift in trafficking routes and rising numbers of 
first-time admissions to specialised treatment. Drawing on 
FIgURE 3. Publications on the topic of cannabis
FIgURE 4. Trendspotter study on Europe's cocaine market
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the agency’s innovative ‘trendspotter’ methodology, the new 
publication looks behind the scenes at factors driving these 
developments (see Key area 3). In December, the EMCDDA 
released a user-friendly guide that takes the reader step 
by step through the trendspotter methodology, which was 
developed by the agency to explore emerging drug trends, new 
patterns of use and developing drug markets and technologies.
Finally, the EMCDDA and Europol released a poster entitled 
Darknet markets ecosystem — Lifetimes and reasons 
for closure of over 100 global darknet markets offering 
drugs, sorted by date. Darknet markets — also known as 
cryptomarkets — provide a largely anonymous platform for 
trading in a range of illicit goods and services. This poster 
is based on a graphic developed for the joint EMCDDA-
Europol publication Drugs and the darknet: perspectives 
for enforcement, research and policy, which was released in 
November 2017. 
Prevention and harm reduction
There is growing recognition of the important role that 
environmental factors play in health-related behaviour. In a 
report published in May — Environmental substance use 
prevention interventions in Europe — the EMCDDA offers 
the first operational definition of the concept and provides an 
initial overview of where and how such interventions are being 
used in the region. 
As part of the Perspectives on Drugs series, in October, the 
EMCDDA launched an analysis on Preventing overdose 
deaths in Europe. This analysis describes some of the factors 
that increase the risk of fatal and non-fatal overdoses and a 
number of interventions that have been developed to prevent 
such events.
In addition, the EMCDDA released a technical report entitled 
Monitoring drug use in recreational settings across Europe: 
conceptual challenges and methodological innovations, which 
explores how data on drug use are captured through surveys 
of targeted populations in recreational settings.
In December, an EMCDDA Paper was published entitled 
m-Health applications for responding to drug use and 
associated harms. This paper presents the results of a scoping 
study on the availability of smartphone-based applications in 
the drugs field, which was set within both a European and a 
global context. It explores the range of m-health applications 
that are available to users and professionals who are seeking 
information, support and advice in a wide range of EU 
languages.
The EMCDDA also released a topic overview entitled Viral 
hepatitis policies in Europe. Hepatitis C virus infection is the 
most common infectious disease in PWID, among whom it is 
usually transmitted through the sharing of syringes and other 
drug-use equipment.
Finally, in November, a topic overview entitled EU Early 
Warning System on NPS was published (see Key area 2).
Other joint publications
Working in partnership with ECDC was an important 
component of the EMCDDA’s work programme for 2018. 
Among the initiatives undertaken with ECDC was a joint threat-
assessment mission to Luxembourg (see the next section, 
‘Services: support to policy’) and the release of public health 
guidance on several topics:
  Public health guidance on active case finding of 
communicable diseases in prison settings, which 
provides scientific advice on the different options for 
active case finding among people in prison with the aim 
of diagnosing a range of communicable diseases early 
(released in May); this publication followed a systematic 
review on the same topic, published in November 2017;
  Public health guidance on prevention and control of 
blood-borne viruses in prison settings, in which ECDC 
and the EMCDDA outline evidence-based and effective 
measures to help prevent and control the transmission 
of blood-borne viruses in prison settings (published on 
23 July); this guidance was launched at the International 
AIDS Conference in Amsterdam (AIDS 2018) and 
was accompanied by both a systematic review and a 
publication entitled Guidance in brief, which provides a 
summary of selected findings (see Key area 3). 
I Services: support to policy
EU level
In 2018, the EMCDDA continued to support drug policy 
dialogue at the EU level by providing expertise and technical 
information to the EU institutions (the EP, the Council of the EU 
and the EC). 
A key role was played by the EMCDDA Director, who 
participated in various events held by these three institutions, 
delivered numerous presentations and was involved in 
exchanges with members of the EP (MEPs) and high-level 
representatives of the Council and of the EC, either in Brussels 
or at the EMCDDA in Lisbon (see also the section in Chapter 3 
entitled ‘Corporate area Governance’). 
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This included the Director’s participation at the session entitled 
‘Multidisciplinary approach in the area of Internal Security: the 
EU Policy Cycle for organised and serious international crime 
2014-2017 — policy debate’ at the Justice and Home Affairs 
(JHA) Council meeting on 5 June in Luxembourg. The Director 
participated in this meeting at the invitation of the Bulgarian 
Presidency of the EU. Another example of the Director’s role 
was his participation, on 4 December, in the high-level panel 
discussion entitled ‘EU 2019-24: how can we support viral 
hepatitis elimination in line with the WHO Global Strategy and 
UN SDGs?’ (5) held at the EP. 
Other EMCDDA staff members contributed with technical 
input and gave presentations at key drug-related policy events 
organised by the above-mentioned EU institutions in Brussels 
or in other Member States. This included the EMCDDA 
Scientific Director’s participation in the seminar entitled 
‘Addressing new drug threats. A European perspective’, which 
was organised by the EP Office in Dublin on 23 February. Other 
examples include the meetings of the Horizontal Working Party 
on Drugs (HDG), which took place throughout the year under 
the Bulgarian and the Austrian Presidencies of the Council of 
the EU, as well as the two national drug coordinators’ meetings 
held under the same Presidencies (in Sofia on 3 May and 
in Vienna on 7-8 October). A full list of events attended by 
EMCDDA staff members in 2018 can be found in Annex 5.
In addition to contributing to key drug events organised by 
the EU institutions, the EMCDDA responded to 45 requests 
for input or technical advice on important core business or 
institutional topics. 
Throughout 2018, the EMCDDA also continued to contribute 
to key policy documents. To that end, the agency fulfilled 
the tasks assigned to it within the EU Agenda on Security 
2015-20. The core tasks were to support the multi-annual EU 
Policy Cycle for organised and serious international crime, in 
particular the priorities set by COSI on heroin, cocaine and 
synthetic drugs in the annual European Multidisciplinary 
Platform Against Criminal Threats (EMPACT) operational 
action plans (OAPs). This included providing training to law 
enforcement professionals (see the section entitled ‘Training 
activities organised with CEPOL’ in ‘Services: support to 
practice’), supporting Europol in reporting on synthetic 
drugs and cocaine production sites, contributing to EMPACT 
technical meetings, and providing input and support during the 
drafting of the next EMPACT OAPs. 
The EMCDDA is a key contributor to EU policymaking in the 
NPS area (see also Key area 2). To that end, following the 
proposals of the EC, based on the risk assessment reports 
submitted by the EMCDDA, the Council decided in 2018 that 
ADB-CHMINACA, CUMYL-4CN-BINACA, cyclopropylfentanyl 
and methoxyacetylfentanyl should be subject to control 
measures across Member States. This is the ultimate EU policy 
response to the NPS phenomenon and it shows the agency 
has had significant input into EU policymaking. 
Throughout the year, the EMCDDA continued to strengthen 
its cooperation with the relevant EC services, in particular 
with the Directorate-General for Migration and Home Affairs 
(DG HOME), the agency's partner Directorate-General. The 
EMCDDA Director met with the Cabinet of Commissioner 
Avramopoulos and the Director-General of DG HOME, 
Paraskevi Michou, as well as with the Deputy Director-General, 
Olivier Onidi. The new Director for Security at DG HOME, 
Laurent Muschel, paid a visit to the EMCDDA on 18-19 
October. Several meetings were held with Ms Floriana Sipala, 
Head of the Organised Crime and Drugs Policy Unit at DG 
HOME. Further coordination meetings took place with the 
EC during the year and briefing notes were provided when 
requested.
The EMCDDA also participated in and delivered presentations 
at a meeting of the HIV/AIDS, Hepatitis and Tuberculosis Think 
Tank, which was organised by the Directorate-General for 
Health and Food Safety (DG SANTE) and held in Luxembourg 
on 15-16 May, and at the fourth HIV/AIDS, Hepatitis and 
Tuberculosis Think Tank, which was held in Brussels on 7-8 
November.  
The agency was also very active in providing support to the 
Directorate-General for Neighbourhood and Enlargement 
Negotiations (DG NEAR) and the European External Action 
Service (EEAS) on activities with third countries. This included 
contributions to the 2018 Enlargement package of the EC and 
to the Mini-Dublin Group report on Bosnia and Herzegovina 
and selected neighbouring countries, as well as ad hoc support 
to the second phase of the COPOLAD (COPOLAD II) and 
phase 5 of the Central Asia Drug Action Programme (CADAP 
5), both projects of the EC. It is also worth noting that the 
EMCDDA Director participated in the Technical Assistance 
and Information Exchange (TAIEX) 19th International Forum 
for Prosecutors on Fighting Cross-Border Organised Crime 
(2-4 October, Lisbon), as well as in the review of the TAIEX 
Peer Review Mission Report on Drug Demand and Supply 
Reduction in Bosnia and Herzegovina: Institutional Set-up and 
Cooperation.
In the drug research area, the EMCDDA, at the request of DG 
HOME, continued its activity as a member of the evaluation 
committee in charge of assessing the proposals submitted 
under the ‘Supporting Initiatives in the Field of Drugs Policy’ 
2018 call. Furthermore, the agency supported its Scientific 
Committee in preparing and delivering to the HDG its input 
into the Annual Dialogue on Research. 
(5) UN SDgs refers to the United Nations Sustainable Development goals.
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In terms of services provided to policymakers, the EMCDDA’s 
cannabis policy news service (see Figure 5), which was 
launched in 2016, continued to provide regular alerts to its 
subscribers. Six alerts were sent in 2018, while the number of 
subscribers nearly doubled during the year (i.e. from 165 as of 
1 January to 315 as of 31 December). 
In 2018, the EMCDDA also continued to provide appropriate 
technical backstopping to support the EU in external dialogues 
with international bodies and third countries. A key event 
was the 61st Session of the Commission on Narcotic Drugs 
(Vienna, 12-16 March). The EMCDDA participated in various 
sessions, gave six talks in side events, attended the EU-Brazil 
dialogue and supported the EU and its Member States in their 
normative deliberations.
Member States
Throughout the year, the EMCDDA maintained communication 
with the Member States, in particular with the agency’s main 
national partners and data providers, the Reitox network of 
NFPs (see Cross-cutting area A). 
The EMCDDA Director paid high-level institutional visits to 
Lithuania (15 May), Germany (1 October), Cyprus (10 October), 
Estonia (6 November) and France (5 December). EMCDDA 
staff also went on a mission to support the national launches 
of the 2018 EDR in six EU Member States (Bulgaria, Czechia, 
Croatia, Cyprus, Poland and Romania) and Norway.
Further technical missions were carried out at the invitation 
of national authorities to support different countries’ drug 
initiatives. 
In March, ECDC and the EMCDDA responded to a request 
by the Ministry of Health of Luxembourg to conduct a joint 
country mission to review the observed increase in reported 
HIV cases among PWID in Luxembourg and to propose key 
actions.
During a four-day visit to Luxembourg, the mission team 
visited services for PWID, including needle and syringe 
exchanges at mobile and fixed sites, a drug consumption 
room, opioid substitution treatment services, residential drug 
services and prison services. The team met with clinicians 
involved in HIV care for PWID, teams delivering drug treatment, 
representatives responsible for HIV surveillance activities, the 
National Drug Coordinator, staff involved in the provision of 
services for homeless/socially excluded individuals, and non-
governmental organisations engaged in HIV testing, prevention 
and control. In addition to the mission, the Luxembourgish 
health authorities were provided with a joint ECDC-EMCDDA 
technical report that presented the findings of the mission and 
a set of recommendations to tackle the specific situation in 
that country. 
Another example of the EMCDDA’s work with Member States is 
the support provided to Estonia. In April, the country submitted 
a formal request to the EMCDDA, asking for technical support 
in the evaluation of Estonia's drug prevention policy, which 
was adopted in 2014. In response to this request, EMCDDA 
experts carried out a technical mission to Tallinn in May, where 
they met national policymakers and discussed steps towards 
developing structures and methodologies for the evaluation 
of the Estonian national drug strategy and action plan. Further 
advice and methodological support was provided during 
2018 to the core group of Estonian officials involved in the 
evaluation process.
At the request of several countries, the EMCDDA 
also examined the new trend of the sale of low- 
tetrahydrocannabinol (THC) cannabis. Herbal cannabis, 
cannabis resin and cannabis oils are openly being offered 
for sale, with the claim that they are below specified national 
limits of THC (0.2 % or similar). This has raised concerns, 
including concerns regarding whether or not these claims are 
accurate, the possible health or social harm created through 
this type of cannabis attracting new users and the challenges 
of law enforcement in distinguishing between low- and high-
THC cannabis on the street. The issues and possible solutions 
were discussed at the Legal and Policy Correspondents 
meeting in June, which was followed by a cannabis policy 
news alert in October and a meeting of experts in November, 
including food safety and medicines law experts, as well as 
sellers of these products. A report collating the results of all of 
this, plus information from the NFPs, will be published in 2019.
An EMCDDA Policy Evaluation Workshop took place in 
Lisbon on 19-20 November. The aim of the workshop was to 
build up the knowledge and expertise of those engaged in 
commissioning, managing and making use of evaluations of 
FIgURE 5. Flyer promoting the cannabis drug policy news 
service
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policies and strategies in Member States in order to strengthen 
the design, management and use of policy evaluation, with 
a particular focus on building an evaluation culture and 
improving the availability of indicators. Very positive feedback 
was received from the participants, namely experts from 
Estonia, Ireland, Cyprus, Austria and Portugal. 
The EMCDDA also received visits from high-level 
representatives or ambassadors from several Member States, 
including visits from the Minister of Health from Luxembourg 
and from the Minister-President of the Brussels Region, as 
well as visits from the ambassadors from Belgium, Germany, 
Estonia and Austria.  
I Services: support to practice
Knowledge exchange is one of the EMCDDA’s key tasks. This 
involves the dissemination of best practice and the design and 
implementation of capacity-building and training initiatives for 
different audiences. 
Best practice portal
Identifying and disseminating information on the effectiveness 
of interventions across the EU and beyond is one of the 
EMCDDA’s core tasks. The main dissemination channel is the 
BPP. The BPP is designed to help practitioners find reliable 
information on what works (and what doesn’t) in the areas of 
prevention, treatment, harm reduction and social reintegration. 
In 2018, some parts of the BPP became available in 
eight languages: English, French, German, Italian, Polish, 
Portuguese, Russian and Spanish.
The BPP is reinforced by the results of the Cochrane Group on 
Drugs and Alcohol. As part of a visit by the Chief Executive 
Officer of the Cochrane Collaboration, Mark Wilson, to the 
EMCDDA in March, ways in which the EMCDDA and the 
Cochrane Collaboration may strengthen their efforts to 
promote evidence-based recommendations and support 
successful implementation strategies were further explored.
In November, the EMCDDA organised an expert meeting to 
examine the implementation of evidence-based interventions 
on drugs. Experts in the implementation of evidence-based 
interventions from Europe and North America gathered at the 
EMCDDA for the agency’s first ‘Pathways to implementation’ 
technical meeting.
During 2018, the BPP included, among others, updates on:
  how to respond to benzodiazepines and synthetic opioids
  how to respond to multiple risk behaviours
  behaviour change in the context of substance-use 
treatment
  health interventions in prison
European prevention conference in Lisbon
The EMCDDA strives to support evidence-based prevention 
and to promote greater use of interventions that have 
been proven to be effective. In 2018, this included further 
implementation of the European Universal Prevention 
Curriculum (EUPC).
The ninth annual conference of the EUSPR took place in 
Lisbon from 24 to 26 October (see Figure 6). The event, which 
was entitled ‘Prevention technologies — improving the use 
of evidence in prevention practice’, was co-organised by the 
EUSPR and the EMCDDA. 
During the meeting, the Review Board of the Xchange registry 
of evidence-based prevention interventions met and discussed 
the inclusion of additional entries on substance use, as well 
as new entries targeting other risky behaviours, such as 
delinquency and violence. As a result, 11 new programmes, on 
crime and delinquency, have been added to the database of 
programmes.
FIgURE 6. 9th EUSPR conference in Lisbon
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In November, a Reitox Academy took place in Prague entitled 
‘Scaling-up prevention: Universal Prevention Curriculum’ 
(UPC). It was organised by the EMCDDA and the UPC-ADAPT 
group, in collaboration with the First Faculty of Medicine 
of Charles University in Prague and the Czech National 
Monitoring Centre for Drugs and Addiction. 
The final UPC-ADAPT dissemination conference was held 
in conjunction with the above-mentioned EMCDDA Reitox 
Academy (in Prague). UPC-ADAPT has generated a set of 
curricula for use in the training of prevention professionals in 
Europe. Nine EU Member States (Belgium, Czechia, Germany, 
Estonia, Spain, Croatia, Italy, Poland and Slovenia) piloted 
these materials in 2018. The EMCDDA took the lead in 
finalising the EUPC training manual (the main output of the 
UPC-ADAPT project financed by the Justice Programme), 
which will be published in 2019. 
The EMCDDA Director also delivered a significant number of 
presentations at scientific and practice events (for details, see 
the section in Chapter 3 entitled ‘Corporate area Governance’).
Training and capacity building
Another effective means of supporting practice is through 
training and capacity-building activities. During the year, 
several such events took place, including Reitox Academies 
and training initiatives in cooperation with traditional partners, 
such as ISCTE-IUL and CEPOL.
Reitox Academies
The Reitox Academies are the main capacity-building initiative 
of the EMCDDA and they are run in collaboration with, and 
for the benefit of, its partners in the Member States and third 
countries. 
Seven Reitox Academies and training sessions were organised 
in 2018 for 201 professionals from EU Member States and 
non-EU countries. Further details are presented in Cross-
cutting areas A and C. 
Furthermore, at the request of the Bulgarian authorities, the 
EMCDDA contributed to the organisation of three training 
sessions for the Bulgarian National Drug Center for a total of 
105 participants (for details, see Cross-cutting area A).
European Drugs Summer School 
The seventh edition of the joint ISCTE-IUL and EMCDDA 
European Drugs Summer School was successfully organised 
and positively evaluated by students and lecturers. With a 
record number of participants, the 2018 edition was focused 
on the prevention of substance use in Europe. A total of 53 
students, from 25 countries across the world, arrived in Lisbon 
for two weeks (25 June-6 July) of intensive training and 
engaging networking. 
European drugs summer school, class of 2018
© ISCTE-IUL, Hugo Alexandre Cruz
I think that the Drugs Summer School was excellent: 
very interesting programme, good lecturers, interesting 
students with various backgrounds, good mix between 
theory and practice and visits.
Testimonial from Mailys Ramonatxo, General Secretariat 
DGD — Justice and Home Affairs, Council of the EU
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Training activities organised with CEPOL 
As part of its contribution to the EMPACT OAPs of the EU 
Policy Cycle on organised and serious international crime, in 
2018 the EMCDDA continued to organise training activities for 
law enforcement professionals with its partner CEPOL. To that 
end, the agency’s staff participated as experts in six training 
initiatives (both webinars and residential sessions)  
(see Table 1). 
In 2018, in partnership with CEPOL, the EMCDDA developed 
and implemented, for the second time, a three-day residential 
training course on ‘Drug markets and drug-related crime: 
strategic analysis’, which was based on the EU Drug Markets 
Report published in 2016 jointly by the EMCDDA and Europol. 
The course, which was held in Lisbon, was attended by senior 
law enforcement officers from EU Member States, Kosovo and 
Switzerland.
I Dissemination of results and evidence
The EMCDDA’s digital channels
Online communication is the agency’s preferred channel 
for disseminating up-to-date knowledge on all facets of the 
drug situation, with the EMCDDA website at the core of this 
effort. Social media and multimedia channels are used to alert 
audiences to upcoming events, communicate findings and 
engage more actively with audiences in real time. Figure 7 
outlines the activities undertaken by the agency through online 
communication channels. 
In April, the EMCDDA launched its new Document Library  
(see Figure 8), namely an online resource aimed at researchers 
in the field of drugs and addiction in Europe. This searchable 
catalogue provides quick-and-easy access to a wide range of 
drug-related material. The library is being added to on a daily 
basis and currently includes EMCDDA-commissioned reports, 
EU and national drug policy documents, scientific papers 
published by EMCDDA staff and a selection of key resources 
from partner organisations. 
TAblE 1. Training initiatives organised with CEPOL in 
2018: activities and number of participants
Course Residential participants
Cannabis production and smuggling 35
Cocaine smuggling 40
Heroin smuggling 38
Drug markets and drug-related crime: 
strategic analysis 
28
Dismantling illicit laboratories 30
Synthetic drugs  30
Total 201
Source: CEPOL.
FIgURE 7. EMCDDA online communication channels
FIgURE 8. EMCDDA Document Library
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In addition, the EMCDDA has created a media library on its 
website, providing easy access to infographics, videos, photos 
and interactive features.
In December, a ‘Seasonal calendar’ campaign was launched 
on all EMCDDA social media channels — Facebook, Twitter, 
LinkedIn and Instagram. The aim of the campaign was to 
promote the high number of new products that were published 
during the month and also to highlight key resources published 
throughout the year. To this end, a short video was released 
each day between 1 and 24 December revealing a new 
resource. These ‘mini videos’ were uploaded as native videos 
on the channels and embedded in Instagram Stories with 
additional hashtags and links.
Visits to the EMCDDA 
Another of the EMCDDA’s means of disseminating knowledge 
is through the presentations delivered to visitors to the 
agency’s headquarters in Lisbon. There have been 55 visits 
in 2018 (i.e. more than one visit per week, on average), with a 
total of 542 visitors. 
I Early warning and threat assessment    (Key area 2) 
I Responding to NPS ― EU Early Warning System  and risk assessment
The year 2018 brought an important change in the 
implementation of the EU EWS on new drugs. From 23 
November 2018, Council Decision 2005/387/JHA was 
repealed. The procedures regarding information exchange on, 
and an early warning system and risk assessment procedure 
for, new psychoactive substances are now included in the 
amended Regulation (EC) No 1920/2006 and the amended 
Council Framework Decision 2004/757/JHA. This new legal 
instrument retains the three-step approach to responding  
to NPS — early warning, risk assessment and control 
measures — while significantly strengthening existing 
processes by streamlining and accelerating data collection and 
assessment procedures. 
Therefore, while an important part of the agency’s resources in 
this area were dedicated to adapting the relevant guidelines, 
procedures, processes and tools to the new legal framework, 
and ensuring a smooth transition between the two legal 
instruments, the EMCDDA continued to ensure the robust 
implementation of the EU EWS, together with its partners 
in the Member States (the Reitox network of the EWS 
correspondents), Europol and EMA.
The partnership will be further strengthened under the new 
legal framework, which will entail cooperation with three new 
EU agencies: ECDC, ECHA and EFSA. To that end, working 
arrangements were concluded with these agencies (in 
December 2018 with ECDC and in February 2019 with ECHA 
and EFSA), while the existing working arrangements with EMA 
and Europol were updated and signed in December 2018, in 
order to accommodate the changes. 
Key outputs of the EWS have included rapid notifications 
and public health alerts on NPS, the exchange of forensic 
and toxicological analytical data, and outputs related to the 
implementation of the Council Decision (until 22 November 
2018) and the risk assessment mechanism. 
In a nutshell, the EMCDDA’s main activities in this area were as 
follows (see also Figure 10):
  The network was notified of 55 NPS, including six new 
fentanils.
  Around 730 NPS were monitored by the EU EWS, as of the 
end of 2018 (6).
  Two EMCDDA-Europol joint reports, namely on 
cyclopropylfentanyl and on methoxyacetylfentanyl, were 
published in the EMCDDA layout in February 2018. 
FIgURE 9. Europe gets stronger system to tackle new 
psychoactive substances
EUROPE GETS STRONGER SYSTEM TO TACKLE NEW PSYCHOACTIVE SUBSTANCES
New legislation, bringing faster response to new drugs 
New legislative package Shorter deadlines
Unchanged three-step approach
Regulation
Directive
Regulation (EU) 2017/2101 of the 
European Parliament and of the Council 
of 15 November 2017 amending Regulation 
(EC) No 1920/2006 as regards information 
exchange on, and an early warning system 
and risk assessment procedure for, 
new psychoactive substances
Directive (EU) 2017/2103 of the European 
Parliament and of the Council of 15 
November 2017 amending Council 
Framework Decision 2004/757/JHA in 
order to include new psychoactive substances 
in the denition of ‘drug’ and repealing Council 
Decision 2005/387/JHA
I. Information exchange
Early-warning system (EWS) Initial reports
III. Decision-making Control measures
II. Risk assessment Risk assessments
Launch
2
weeks
5/6
weeks
7/8
weeks
10
weeks
13/14
weeks
26
weeks
Information 
collection
(optional)
Initial report/ 
Combined initial
reports
Risk assessment 
requested
Risk assessment 
report
Information
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EMCDDA-Europol
Joint Report
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Council Decision
2005/387/JHA
Regulation (EC) 
1920/2006 as 
amended by 
Regulation (EU) 
2017/2101
Risk assessment
requested
(6) For the last year for which data is complete (2017), more than half  
(392 substances) of the substances monitored by the EU EWS at that time were 
detected again across Europe.
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These reports were prepared and submitted to the EU 
institutions in 2017.
  Two risk assessments, namely on cyclopropylfentanyl 
and on methoxyacetylfentanyl, were carried out by the 
EMCDDA’s Extended Scientific Committee on 21 March, 
and the risk assessment reports were subsequently 
submitted to the EU institutions, as stipulated by the 
Council Decision.
  Nine risk assessment reports were published, namely 
the reports that followed the two risk assessments 
conducted in 2018 (see the point above) and seven 
risk assessment reports of the nine risk assessments 
conducted in 2017, namely risk assessment reports on 
AB-CHMINACA, ADB-CHMINACA, 5F-MDMB-PINACA, 
CUMYL-4CN-BINACA, 4-fluoroisobutyrylfentanyl (4F-iBF), 
tetrahydrofuranylfentanyl (THF-F) and carfentanil.
  Seven risk communications were published (five 
advisories and two briefings) and two updates were issued 
to the EWS network.
  Following the proposals of the EC, based on the 
risk assessment reports submitted by the EMCDDA, 
the Council of the EU decided on 14 May that ADB-
CHMINACA and CUMYL-4CN-BINACA should be subject 
to control measures at the EU level. Two more substances, 
namely cyclopropylfentanyl and methoxyacetylfentanyl, 
were subjected to similar control measures on 28 
September, following the Council’s implementing decision.
Some of the EMCDDA’s central activities continued to 
be network management and the provision of technical 
assistance on a daily basis to the members of the Reitox EWS 
network in 2018. Literature searches were performed for all the 
substances that were detected for the first time in Europe and 
the EU EWS network was formally notified of these. In addition, 
structured data were collected periodically on all monitored 
substances, and trends in the NPS market were identified and 
analysed. 
The 18th Annual Meeting of the Reitox EWS network took place 
on 5 and 6 June. All of the presentations given at this meeting 
and the minutes of the proceedings were published in the 
European Database on New Drugs (EDND). 
In accordance with Article 10 of the Council Decision, the 
EMCDDA-Europol 2017 annual report on the implementation 
of Council Decision 2005/387/JHA was prepared by these two 
agencies, submitted to EU institutions in July and published 
in August. The report presented the key activities performed 
by the EMCDDA and Europol in 2017, including the list of NPS 
of which the EWS was notified, the joint reports produced, 
the risk assessments conducted and the public health alerts 
issued. This was the last annual report on the implementation 
of Council Decision 2005/387/JHA produced by the two 
agencies; following the application of the new legal instrument 
on NPS, this report will no longer be required. 
The Rapid Communication Fentanils and synthetic 
cannabinoids: driving greater complexity into the drug 
situation — an update from the EU Early Warning System 
was published in June. This publication provides insights into 
what is happening with NPS in Europe, based on data from 
the agency’s early warning and risk-assessment activities. The 
report covers the period from January 2016 to  
December 2017.
Furthermore, a topic overview on the EU EWS on NPS was 
released in November 2018. It describes the work and main 
outputs of the EU EWS and includes a description of how 
the system works, an historical timeline of legislation and the 
substances investigated, and NPS drug profiles. 
Information exchange with EMA and the EU pharmacovigilance 
system on medicines and substances with medicinal 
properties was ongoing in 2018. The two agencies continued 
to strengthen their collaboration in accordance with their roles 
under Council Decision 2005/387/JHA, Regulation (EU) No 
1235/2010 and the working arrangements in place. 
In recent years, there has been an increase in the number 
of medicinal products monitored by the EMCDDA under the 
EWS. In turn, this has led to an increase in the number of 
requests made to the EMCDDA by the Pharmacovigilance Risk 
Assessment Committee of EMA regarding information on such 
medicines, after signals related to their misuse and abuse are 
identified by the EWS. 
FIgURE 10. Early Warning System and risk assessment: 
key facts and figures
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The Toxicovigilance System of the EWS was further developed. 
With a view to detecting signals of NPS that pose health 
concerns, daily searches and reviews of major English-
language open source information, including scientific and 
medical literature, were performed. 
The agency also actively cooperated with international bodies, 
particularly with the United Nations Office on Drugs and 
Crime (UNODC) and the World Health Organization (WHO) 
in Geneva, to support prioritisation, scheduling discussions 
and information exchange activities and meet the need to 
respond at the international level to the harm caused by NPS. 
A list of substances was provided by the EMCDDA on 13 April 
to assist in the prioritisation of substances to be reviewed 
during the 41st Expert Committee on Drug Dependence 
meeting. Furthermore, the EMCDDA participated in the fifth 
WHO/UNODC Expert Consultation meeting, which was held in 
Geneva in September. 
The EMCDDA and the UNODC also strengthened their 
collaboration as regards the collection of data related to the 
identification and seizure of NPS in Europe. This collaboration 
is based on the recognition of the world-leading role played 
by the EU EWS and the EMCDDA in the early identification 
of threats related to NPS. The list of NPS that the EWS was 
notified of was shared by the EMCDDA with the UNODC. 
As part of the cooperation with enlargement countries, 
support under the EC-funded IPA 6 project (for details, 
see Cross-cutting area C) was also provided to candidate 
countries and potential candidate countries to design and 
operate an EWS at the national level (NEWS). To that end, the 
exchange of communication on news related to NPS and the 
EWS in Europe was ongoing between the EMCDDA and the 
beneficiaries’ representatives. 
Furthermore, representatives of four candidate countries 
and potential candidate countries attended the 18th Annual 
Meeting of the Reitox EWS network in June. On that occasion, 
a satellite meeting took place and the EMCDDA presented 
the guidelines to be used by the countries when drafting their 
NEWS profiles. 
An important activity undertaken in 2018 was the assessment 
of the national drug observatory and the national early 
warning system, which was carried out by the EMCDDA in 
Serbia (12 and 13 June) and Montenegro (14 and 15 June). 
In terms of the NEWS, the assessment took place against 
the requirements of the EU legal framework in place and 
the working methods established by the EU EWS as laid out 
in the early warning system and risk assessment operating 
guidelines, and in line with the established working practices 
within the EMCDDA and the EU Member States. 
The reports highlighting the main conclusions and 
recommendations for each country were subsequently 
prepared by the EMCDDA and forwarded to the relevant 
national authorities in October. A roadmap to implement the 
EMCDDA recommendations was also developed, together with 
DG NEAR, for Montenegro.
Capacity building in this area also included the Reitox 
Academy for Serbia on the following topic: ‘NPS: Definition, 
situation and treatment’. It took place on 20 December in 
Belgrade and was attended by 25 participants. The event, 
which was organised at the request of the Serbian national 
drug coordinator, aimed to clarify what an NPS was and outline 
the classification and health effects of NPS, to discuss the 
situation of NPS in Europe and in Belgrade, and to improve 
participants’ knowledge on the demand for and harm-
reduction responses to NPS. 
The EMCDDA provided its leading expertise to the project 
COPOLAD II (for details, see Cross-cutting area C).
I Emerging trends and threats 
The detection and monitoring of new trends and threats 
remained one of the key tasks of the agency in 2018. 
The activities in this field reflect an increasing recognition 
of the importance of facilitating the development of early 
responses to potential threats by strengthening the systems 
for identifying and tracking new and emerging trends. 
EMCDDA trendspotter methodology
The trendspotter method (see Figure 11) involves the rapid 
collection and triangulation of data from a variety of sources, 
incorporating multiple social research methods and drawing 
on rapid assessment and response methods. In December, the 
EMCDDA published its Trendspotter manual: a handbook for 
the rapid assessment of emerging drug-related trends.
The EMCDDA carried out a trendspotter study on ‘Recent 
changes in Europe’s cocaine and crack market’. The study 
investigated the consequences of these developments on 
the acute health effects linked to cocaine and crack use and 
reviewed the current public health responses to problems 
related to these drugs. The results of the study were published 
FIgURE 11. Trendspotter process
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in December in the form of a Rapid Communication  
(see Key area 1).
Finally, a trendspotter study carried out in 2017 on NPS in 
prisons identified growing evidence that NPS are responsible 
for a large proportion of the drug-related problems in some 
European prisons. The results of the study were published in 
June 2018. In addition, two videos on the topic were released 
by the EMCDDA.
In November 2018, the results of a training workshop on 
the trendspotter methodology, delivered by the EMCDDA at 
the Second COPOLAD II Annual Meeting of National Drugs 
Observatories in 2017, were published as joint EMCDDA-
COPOLAD report (see Cross-cutting area C).
During 2018, the EMCDDA continued providing support to the 
national trendspotter activities, which were initiated in 2017.
Wastewater analysis and drugs
In 2018, the EMCDDA continued its collaboration with SCORE. 
This Europe-wide network works to standardise the approach 
to wastewater analysis and coordinates national studies by 
analysing wastewater in almost 60 European cities to explore 
the drug-taking behaviours of their inhabitants. The latest 
findings were released in March as an updated Perspectives 
on Drugs publication, Wastewater analysis and drugs — a 
European multi-city study. The findings offer a valuable 
snapshot of the drug situation in the cities involved, revealing 
marked regional variations in drug-use patterns. The findings 
were published in various languages (see Figure 12). 
In addition, an expert meeting on wastewater-based 
epidemiology was organised by the EMCDDA on 18-19 
September.
European Drug Emergencies Network (Euro-DEN)
The Euro-DEN Plus project collects data on acute recreational 
drug and NPS toxicity from sentinel hospital emergency 
rooms across Europe. It has expanded from the original 
16 centres in 10 countries (2013/14) to 32 centres in 22 
countries (2018/19) to increase the geographical reach and 
representativeness of the dataset. Over the last year, more 
than 7 200 presentations of recreational drug use in hospital 
emergency rooms were reported. On 4-5 December, the 
EMCDDA hosted the Euro-DEN Plus Research Group meeting, 
including clinicians from the network as well as experts from 
the NFPs. The aim was to discuss the most recent data and 
future developments.
Drug-checking services
On 30-31 October, the EMCDDA organised a meeting 
regarding the collection of data on the analyses of drug 
samples among drug-checking services (see Figure 13). It 
was a meeting of the Trans-European Drug Information (TEDI) 
project, a network of European fieldwork drug-checking 
services that share their expertise and data within a European 
monitoring and information system. The TEDI project has 
developed a database system that collects, monitors and 
analyses the evolution of various European drug trends in 
recreational settings. The TEDI project was financed by the EC 
from 2011 to 2013. Since 2017, thanks to collaboration with 
the EMCDDA, TEDI is building a new database and reported 
its first data collection to the EMCDDA in 2018. In October, 
the EMCDDA hosted an expert meeting on the data collection 
FIgURE 12. Wastewater analysis and drugs — available in English, French, Spanish, Portuguese and German
FIgURE 13. Drug checking services in Europe
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of results from analyses of drug samples from drug-checking 
services in Europe.
I Situation, responses and trend analysis    (Key area 3) 
This area includes the EMCDDA’s core monitoring and analysis 
activities. As part of this area, the EMCDDA provides an annual 
state-of-the-art overview of drug demand and supply, including 
its suggested responses for tackling these issues and the 
core trends in these domains. These activities are based on 
established tools and processes that are regularly assessed 
to ensure that they are fit for purpose, complemented by 
the development of new ones as necessary. Together, these 
methodological activities ensure that the EMCDDA’s core 
monitoring system remains relevant and efficient. Moreover, 
it is of the utmost importance that this system provides valid, 
reliable and accurate information, in order to inform sound 
decisions for policy and practice. 
Ongoing monitoring and analytical work was carried out 
throughout the year, and this fed into the key outputs produced 
by the agency. These outputs are mainly presented in  
Key area 1.
I Monitoring drug demand
In terms of monitoring drug demand, the agency relies on 
its well-established key epidemiological indicators, which 
include the prevalence and pattern of drug use in the general 
population (based on a GPS); the prevalence and patterns 
of high-risk drug use (the problem drug use (PDU) indicator); 
the number and characteristics of drug users contacting drug 
services, in particular treatment services (treatment demand 
indicator (TDI)); the number of drug-induced deaths and 
the mortality among drug users (drug-related deaths (DRD) 
indicator); and infectious diseases related to drug use  
(drug-related infectious diseases (DRID) indicator). 
In 2018, a comprehensive triennial review of the 
implementation of the key epidemiological indicators in the 
30 reporting countries was conducted and presented to the 
Management Board in December. The assessment describes 
the progress made since the previous review (2015) and will 
inform work priorities in this area for the following three-year 
period (2019-21).
As before, the knowledge base provided by the key 
epidemiological indicators will be supported by the EMCDDA’s 
Reitox NFPs and other networks of experts that contribute their 
national expertise to the agency’s European drug information 
and analysis system. The interaction with these networks was 
continuous, with regular contact and technical support, and 
culminated in annual expert meetings that were organised by 
the agency at its premises in Lisbon (see Table 2). 
An innovative tool that helps in the rapid reporting of new 
trends is the European Web Survey on Drugs. It is a useful 
method for obtaining information from drug users, in different 
countries in a quick and cost-effective manner, on the amounts 
used, the frequency of use and the sources of supply. 
By mid-January 2018, the European Web Survey on Drugs had 
reached more than 50 000 participants. The survey, which is 
run with a number of Reitox NFPs, collects information from 
different groups of drug users on topics currently not covered 
by routine data collection. 
In addition, the EMCDDA continued its support for the 
development of innovative methods to better monitor new 
trends, including the analysis of syringe residues and pill 
testing. The two pilot projects in these areas, which both 
started in 2017, were further developed in 2018 to explore 
the potential of these tools to improve monitoring and the 
timeliness of reporting on new trends. 
Following the publication of the ESPAD report in 2016, the 
EMCDDA continued to work closely with ESPAD principal 
investigators to make use of the current survey results and 
to coordinate the activities necessary for the next round of 
ESPAD planned for 2019. These activities included organising 
regional seminars, developing the questionnaire and ensuring 
the production of national work plans. In addition, the 
TAblE 2. Main network meetings held in Lisbon in 2018
Meeting Dates
Expert meeting on the prevalence and patterns 
of drug use among the general population 
(based on a gPS) 
15-26 May 
19th Meeting of the legal Correspondents of the 
European legal Database on Drugs (ElDD) 
11-12 June
Expert meeting on the PDU epidemiological 
indicator
19-20 June 
Expert meeting on the DRID indicator 24-25 June 
Expert meeting on the TDI 3-4 October 
Sixth annual meeting of the EMCDDA reference 
group on drug supply indicators 
11-12 October 
Expert meeting on DRD indicator 8-9 November 
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EMCDDA provided support to 11 countries (both EU and 
third countries), helping them to conduct their national data 
collections in 2019.
I Harm-reduction interventions
In May, the EMCDDA launched a three-year initiative with 
the purpose of promoting hepatitis C testing among PWID 
in drug treatment settings. The initiative represents both 
an operationalisation of a central EMCDDA public health 
priority and the implementation of a dynamic intervention 
model presented in Health and social response to drug 
problems: a European guide (2017). In 2018, the guide also 
became available in Russian and Spanish. Through this 
project, the EMCDDA aims to support EU Member States’ 
efforts to improve national practices in the hepatitis C field by 
supporting diagnosis of the national situation, and to provide 
high-quality materials for training activities for those working 
in the field. The kick-off meeting of the initiative was held on 
18-19 January at the EMCDDA.
In 2018, the EMCDDA released two joint public health 
guidance publications and one joint systematic review with 
ECDC (see Key area 1). In addition, the following resources 
were published on the topic of prisons (see also Figure 14):
  Health and social responses to drug problems in prisons 
(EMCDDA commissioned paper);
  European evidence-based guidance on prevention and 
control of HCV in prison settings (poster) and Guidance in 
brief;
  New psychoactive substances in prison (Rapid 
Communication).
The EMCDDA continued its work on the development of new 
methodological frameworks on the mapping of e-health 
and m-health (mobile health) applications. A paper entitled 
m-Health applications for responding to drug use and 
associated harms was released in December, which explores 
the range of m-health applications available to users and 
professionals seeking information, support and advice in a 
variety of EU languages.
On 4-5 June, the EMCDDA organised a technical meeting 
on ‘The role of Drug Consumption Rooms (DCR) as a source 
of information on the drug situation at local, national and 
European level’. 
In this area, the EMCDDA collaborated with the European 
Forum for Urban Security (EFUS) in the framework of the 
EC-funded project 'Solidify — Supervised Drug Consumption 
Facilities to Instill Harm Reduction and Social Cohesion at 
Local Levels', which aims to better equip cities that have DCRs, 
in order to help them accompany and facilitate the installation 
of structures and to evaluate the rooms’ impacts in terms of 
localised nuisance reduction.
Further steps were also made towards improving our 
understanding of the coverage of treatment services across 
the EU. 
I Monitoring drug supply 
In the area of drug supply, work was focused on ensuring that 
all of the reporting instruments were fully implemented and 
on improving the quality and coverage of data collected in the 
Member States.
Significant effort was also put into the preparation of the 
third EMCDDA-Europol EU Drug Markets Report (which will 
be published in 2019). Work is also underway on providing 
a second set of estimates of the market size for cannabis, 
cocaine, amphetamines, ecstasy and heroin, which will be 
published in 2019.
At the end of the year, the EMCDDA and Europol released a 
joint progress report providing an overview of the key findings 
of the implementation of the revised drug supply indicators, 
entitled Improved drug supply indicators for Europe: progress 
report (see Key area 1).
The work of the EMCDDA reference group on drug supply 
indicators, including representatives from each Member State, 
the EC (DG HOME and Eurostat), Europol and Eurojust, was 
essential for reaching the objectives in this area. The annual 
meeting of the group was on 11-12 October.
FIgURE 14. Publications launched in 2018 on prisons
General Report of Activities 2018 Chapter 2 I Core business: monitoring and reporting on the drugs problem 
32 / 87
I Monitoring drug policies and laws
The monitoring of drug laws and policies continued in 2018 
with a focus on emerging issues, such as cannabis policy and 
legislation. A large number of resources on this topic were 
released (see Key area 1). 
The annual meeting of the Legal Correspondents of the ELDD 
was organised on 11-12 June in Lisbon as a means to further 
improve the sharing of knowledge and expertise among 
Member States..
I Information collection and management    (Cross-cutting area A) 
I The annual information-collection exercise
One of the main components of the EMCDDA’s reporting 
system is the national reporting package, which is 
implemented every year in close collaboration with the NFPs. 
This reporting package provides data delivered through a set 
of standard instruments via Fonte (the agency’s online data 
collection system) and a structured commentary on the drug 
situation (the Workbooks), reported via the Reitox extranet. 
Further progress was made in coordinating the data received 
in the Workbooks with that received in Fonte. In 2018, the 
workbook questions for delivery in 2019 were reviewed to 
ensure that they were fit for purpose. The work to establish 
the nature and form of a web-based output (Country Drug 
Reports), which commenced in 2016, was continued in 2018 
(see also Key area 1).
In parallel, the project to align the EDND to the growing 
demands of the EWS continued in 2018. This was 
complemented by the changes that needed to be 
implemented as a result of the application of the new NPS 
regulation (see Key area 2). This technological redevelopment 
of the EDND is a major line of work for the agency and it is 
being undertaken in different phases to ensure that advanced 
technical functionalities are included. The EDND stores the 
information related to all of the NPS monitored to date (some 
730). In 2018, a total of 55 new EDND substance profiles were 
prepared and published for all substances for which the EWS 
had been notified. 
I Management of the Reitox national focal points
In fulfilling its tasks, the EMCDDA relies on the European 
information network on drugs and drug addiction — the 
Reitox network of NFPs. The NFPs play a critical role by 
providing national data from the 30 countries that report to 
the EMCDDA, namely the 28 EU Member States, Norway and 
Turkey. Therefore, the network plays a key role in the successful 
implementation of the EMCDDA Strategy 2025 and the 
achievement of its strategic goals. 
In 2018, the EMCDDA supported the implementation by the 
NFPs of the RDF which was adopted by the heads of the NFPs 
in 2017. The document will ultimately contribute to enhancing 
the visibility, usefulness and sustainability of the NFPs at the 
national level and of the NFPs as a network at the European 
level. The implementation aspects of the RDF, including a 
Roadmap to 2020, were discussed with the NFPs at all of the 
meetings with the NFPs organised by the EMCDDA (see  
Table 3). Furthermore, based on the needs expressed by the 
NFPs in 15 countries, letters were addressed by the EMCDDA 
Director to the relevant high-level national authorities to 
present the RDF to them and ask for their support for the 
concerned NFPs in implementing the document.  
Strengthening the organisational capacity of the NFPs, as a 
means to ensuring their sustainability, was also addressed 
through the accreditation project, which continued in 2018. 
Regular communication was also ensured between the 
EMCDDA and the NFPs throughout the year. Key issues were 
discussed more extensively at the biannual meetings of the 
heads of NFPs (HFPs) and at the two technical meetings 
organised during the year.
TAblE 3. Reitox meetings in 2018
Meeting Dates
58th Reitox HFP meeting 22-24 May 
59th Reitox HFP meeting 14-16 November 
Technical meeting entitled ‘Implementation 
of the Reitox Development Framework and 
Country Drug Reports’
20 March 
Technical meeting entitled ‘Reporting tools, 
lisbon Addictions 2019, Implementation of the 
Reitox Development Framework Roadmap’
2 October 
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Furthermore, six Reitox Academies were organised with Reitox 
NFPs, as follows: 
   ‘Scaling-up prevention: Universal Prevention Curriculum’, 
Prague, 28-29 November (59 participants);
  ‘Communication’, Lisbon, 17-18 October (25 participants);
  ‘Grant agreement management’, Lisbon, 19 October  
(18 participants);
  ‘Refugees, drugs and mental health’, Athens, 21 June  
(31 participants);
  ‘National Academy on monitoring misuse of narcotic 
prescription medicines’, Vienna, 3 December  
(33 participants);
  regional academy for Baltic countries, ‘Harm reduction: 
learning, improving, responding’, Vilnius, 17-19 December 
(10 participants).
In addition, at the request of the Bulgarian authorities, the 
EMCDDA contributed to the organisation of three training 
sessions for the Bulgarian National Drug Center, as follows:
  ‘Modern approaches in prevention’, Sofia, 26-27 February 
(38 participants);
  ‘Treatment of stimulant users’, Sofia, 25-26 April  
(43 participants);
  ‘New Psychoactive Substances: Definition, situation and 
treatment’, Sofia, 27-28 November (24 participants).
Throughout the year, the EMCDDA continued to support the 
work of the NFPs in the implementation of the EMCDDA work 
programme. In the case of the NFPs from the 28 EU Member 
States, a key feature of this support was the co-financing of 
their activities, covered by a grant agreement, without which 
the network could not accomplish its tasks. 
The management of these grant agreements is also part of the 
overall organisational capacity of the NFPs. In the context of 
these grant management activities, the EMCDDA carries out 
regular on-site audit missions: the country randomly covered in 
2018 was Sweden (in October).
I Quality assurance  (Cross-cutting area B) 
In 2018, the EMCDDA continued to improve the quality 
of its analyses and outputs. Ensuring the quality of its 
scientific outputs is essential for the EMCDDA to continue 
to be recognised as the reference point on drugs in Europe; 
therefore, this is an area of critical importance for the agency. 
To that end, further progress was achieved in defining and 
implementing the data quality framework, including the 
indicators for the internal statistics code of practice and 
the documentation regarding data/information flows and 
processes. Efforts were focused on implementing the action 
plan that was put in place to address the recommendations 
of the Internal Audit Service on the management of data 
collection, validation and quality assurance (2017) as well as 
on the preparation and follow-up of the audit on publications 
management (2018).
This included work to assess business needs and the IT tools 
to support them, as well as work on the update of the EMCDDA 
data quality management framework to further align it with the 
EMCDDA Strategy 2025.
One of the key milestones defined in the Strategy 2025 — 
Roadmap 2020 is a Futures exercise. As a result, this was 
launched in 2018, following an inception initiative at the 
Lisbon Addictions 2017 conference. This exercise aims to 
inform the EMCDDA’s thinking on how to keep its tools and 
methods fit for purpose in the context of future regional 
and global developments in drug-related interventions, 
technologies and research methods, as well as in the context 
of wider social developments. One of the milestones of the 
project in 2018 was the conference on ‘Changes in patterns 
of drug use and supply and their implications for monitoring’, 
which was organised in November in Lisbon with the agency’s 
key stakeholders and external experts. In addition to this 
conference, cooperation with the Joint Research Centre (JRC) 
Competence Centre on Foresight was initiated and it was 
agreed that JRC would be involved in the EMCDDA’s ‘Futures 
exercise’.
I Main activities carried out by the EMCDDA    Scientific Committee 
As the guardian of the EMCDDA’s reputation for scientific 
excellence, the Scientific Committee plays a key role in 
assuring and improving the quality of the agency. 
During the year, the members of the Scientific Committee 
adopted a formal opinion on the PD 2019-21 and provided 
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input on the agency’s main projects and scientific publications, 
in line with the guiding principles for the review of selected 
publications. Members of the Scientific Committee were also 
actively involved in the EMCDDA scientific award process, as 
reviewers, nominators of articles and members of the jury
EMCDDA scientific award 
Winners of the 2018 EMCDDA scientific award were 
announced on 14 November at the 49th Scientific Committee 
meeting in Lisbon. The acclaimed writers will be invited to 
Lisbon next autumn to present their articles during the Lisbon 
Addictions 2019 conference. The prize, inaugurated in 2011 
by the EMCDDA and its Scientific Committee, celebrates 
scientific writing and distinguishes high-quality research in the 
field of illicit drugs. In 2018, almost 40 papers were nominated 
by members of the agency’s Scientific Committee, the 
Reitox NFPs, drug research societies with a European focus, 
peer-reviewed scientific journals and EMCDDA staff. The five 
winners (primary authors) were Professor Dr Christian Büchel 
(Germany), Dr Judit Tirado Muñoz, PhD (Spain), Daan van der 
Gouwe (the Netherlands), Professor John Marsden (the United 
Kingdom) and Vendula Belackova, PhD (Czechia).
EMCDDA chairing EU-ANSA 
In 2018, the EMCDDA held the chairmanship of EU-ANSA, 
which promotes cooperation between agencies on issues 
of common interest related to the provision of scientific and 
technical advice and operates under the tutelage and in 
support of the network of Heads of EU Agencies.
The focus of EU-ANSA’s activities in 2018 was on consolidating 
and completing ongoing activities, in areas such as 
communicating scientific uncertainty and continuing work 
on the engagement of EU agencies with the EU research 
knowledge cycle and research clusters.
A paper entitled EU-ANSA agencies’ engagement in the 
European Union research knowledge cycle: an overview was 
published and presented to the Heads of EU Agencies and the 
EC (see Figure 15). This position paper highlights the potential 
added value of the EU-ANSA agencies in identifying knowledge 
gaps and common research and development needs. 
The network held its 11th meeting in Ispra (Italy) on 29-30 May, 
hosted by the JRC, and its 12th meeting in Brussels on 27-28 
November. 
I Cooperation with partners   (Cross-cutting area C)
In line with its strategic priorities, in 2018, the EMCDDA 
continued to enhance the exchange of information and 
knowledge with its European and global partners. Priority was 
given to the activities concerning the provision of technical 
support to EU institutions and the EU Member States (details 
are presented in Key area 1 and in the section in Chapter 3 
entitled ‘Corporate area Governance’). 
Other EU agencies, in particular the ones from the JHA 
network (7), as well as ECDC and EMA, were also key partners. 
Regarding our global partners, cooperation was strengthened 
with international organisations, in particular with the United 
Nations family (the UNODC and WHO). 
In terms of cooperation with third countries, the priorities 
were the successful implementation of the two-year technical 
assistance project IPA 6, which began in July 2017, and the 
preparation of the technical proposal for a new technical 
assistance project, the ‘EU4 Monitoring Drugs’, which has been 
funded by the EC since 1 January 2019.
I Cooperation with EU bodies 
During the year, the successful collaboration developed in 
previous years with other EU agencies continued. It resulted in 
joint outputs, knowledge exchange through technical meetings 
and training initiatives, and input into other joint activities 
(presented in Key areas 1, 2 and 3). 
FIgURE 15. EU-ANSA Agencies Engagement in the EU 
Research Cycle: an overview
(7) The following agencies are part of the JHA network: CEPOl, the European 
Asylum Support Office (EASO), Frontex, Europol, the EMCDDA, the European Union 
Agency for the Operational Management of large-Scale IT Systems in the Area of 
Freedom, Security and Justice (eu-lISA), Eurojust, the European Union Agency for 
Fundamental Rights (FRA) and the European Institute for gender Equality (EIgE).
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At the institutional level, three new working arrangements 
were concluded, namely with Europol, ECDC, and EMA, with 
a view to implementing Regulation (EU) 2017/2101 of the 
European Parliament and of the Council of 15 November 
2017 amending Regulation (EC) No 1920/2006 as regards 
information exchange on, and an early warning system and 
risk assessment procedure for, new psychoactive substances 
and Directive (EU) 2017/2103 of the European Parliament 
and of the Council of 15 November 2017 amending Council 
Framework Decision 2004/757/JHA (see Key area 2 and the 
section in Chapter 3 entitled ‘Corporate area Governance’). 
Two more similar working arrangements were prepared with 
ECHA and EFSA, which were signed in February 2019. 
In addition, throughout the year, the EMCDDA held a number 
of meetings and exchanges with most of the EU agencies, 
namely within the framework of the EU Agencies Network 
and its sub-networks, such as the Performance Development 
Network, the Heads of Communication and Information 
Network, the Heads of Information and Communication 
Technology and other specialised sub-networks. The EMCDDA 
was also an active contributor to the JHA network.
In 2018, the EMCDDA acted as chair of the EU-ANSA after 
having taken over the rotating presidency from ECHA on  
1 January 2018 (for details, see Cross-cutting area B).
I Cooperation with international organisations
Cooperation was strengthened with international organisations, 
in particular with the United Nations family (the UNODC and 
WHO), with a view to maximising synergies and avoiding 
duplication of effort (see also Key areas 1, 2 and 3). 
In 2018, the EMCDDA contributed to technical discussions 
with the UNODC and other international partners on how to 
improve data collection and on how to facilitate inter-agency 
collaboration. A key topic was the revision of the annual report 
questionnaire. The EMCDDA is also an active member of the 
international expert working group on drug epidemiological 
statistics lead by the UNODC and WHO. The agency 
contributed to various other meetings (see Annex 5) and 
welcomed experts from the UNODC and WHO at the events 
organised at its headquarters in Lisbon.
Since 2015, the EMCDDA and the UNODC have been 
strengthening their collaboration with respect to data on 
NPS, namely regarding the identification and seizure of these 
substances in Europe. As part of the ongoing cooperation 
between the EU EWS and the UNODC Early Warning Advisory, 
and in accordance with the agreement between the Reitox 
NFPs and the 30 EMCDDA participating countries, the 
The signing of the working arrangements between the EMCDDA and 
Europol (left: Catherine De Bolle, Executive Director of Europol, and Alexis 
Goosdeel, EMCDDA Director, in the presence of Dimitris Avramopoulos, 
European Commissioner for Migration, Home Affairs and Citizenship);  
the EMCDDA and ECDC (centre: Dr Andrea Ammon, Director of ECDC,  
and Alexis Goosdeel, EMCDDA Director); and the EMCDDA and EMA  
(right: Guido Rasi, Executive Director of EMA, and Alexis Goosdeel, 
EMCDDA Director).
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EMCDDA provides NFP-related data to the UNODC on an 
annual basis. 
The EMCDDA continues to cooperate with both the WHO 
headquarters (Geneva) as well as with the WHO Regional 
Office for Europe (Copenhagen). Cooperation with WHO 
Europe in recent years has covered prisons and infectious 
diseases, whereas cooperation with the WHO headquarters 
has focused on the quality standards of interventions and 
the monitoring of treatment systems. In the area of prisons 
and drug use, the EMCDDA provided expertise to the expert 
meeting and conferences. The EMCDDA is part of the steering 
group of the WHO Europe Health in Prisons Programme 
and attends and actively contributes to their annual prison 
conference and steering group meetings (the last being in  
May 2018). 
During 2018, the EMCDDA also assisted WHO with data for 
the prioritisation process and for the preparation of the critical 
reviews of the 12 psychoactive substances that were reviewed 
by the 41th Expert Committee on Drug Dependence meeting 
(in November). 
The EMCDDA, WHO Europe and ECDC have been working 
closely to assist countries in the elimination of viral hepatitis 
in line with the WHO hepatitis elimination agenda. The 
agencies are contributing to the development of the European 
hepatitis monitoring framework by contributing to experts’ 
meetings, conferences and technical work. In 2018, they 
jointly contributed to the European Association for the Study 
of the Liver (EASL) conference (February), the International 
Network on Hepatitis in Substance Users (INHSU) conference 
(September) and the EMCDDA DRID meeting (September),  
at which issues related to the improvement of data quality and 
availability were presented and discussed with the Member 
States and a wide audience of researchers and practitioners. 
Another of the EMCDDA’s important international partners 
is the Pompidou Group, with which the agency has had a 
Memorandum of Understanding (MoU) since 2001. The areas 
in which these organisations cooperate include drug policies, 
precursors control, prisons, cybercrime, cooperation with  
non-EU countries and providing support for training. The 
EMCDDA was represented at the meetings of The Airport 
Group and the International Network on Precursor Controls 
and participated as an observer at the meeting of the 
Permanent Correspondents (27 November) and at the 17th 
Ministerial Conference of the Pompidou Group (27-29 
November). The agency also attended a MedNet meeting (25-
26 September) and a MedSPAD committee meeting (24 April) 
organised by the Pompidou Group. Furthermore, the EMCDDA 
actively participated in four executive training sessions for 
drug-policy managers on drug-policy evaluation (February, May, 
June and September), in an expert meeting on drug-related 
cybercrime and in a seminar on refugees and drugs, and 
attended the Council of Europe expert meeting on Human 
Rights Education for Legal Professionals.
The EMCDDA also continues to cooperate with the Inter-
American Drug Abuse Control Commission (CICAD-OAS) in 
the framework of the MoU signed in October 2000 and in 
line with the second work programme for the period 2014-
18, which was endorsed in November 2013. During the year, 
the EMCDDA attended a CICAD-OAS training workshop to 
strengthen national drug observatories in Latin America, which 
was held in Antigua, Guatemala, on 7-9 August.
I Cooperation with third countries 
Work in this area is guided by the EMCDDA International 
Cooperation Framework, which was adopted by the EMCDDA 
Management Board in December 2017. In line with this 
document, and following the EU approach for working with 
third countries, first priority is given to the candidate and 
potential candidate countries, followed by the ENP partner 
countries (Eastern and Southern neighbours) and finally by 
other third countries (see Figure 16).  
Candidate and potential candidate countries
EU enlargement countries
In 2018, cooperation between EU enlargement countries at 
the bilateral level was secured by the negotiation of a working 
arrangement with the Republic of Albania, which was initialled 
at the EU-Western Balkans Ministerial Forum on Justice and 
Home Affairs (4-5 October in Tirana). While the EMCDDA has 
signed similar agreements with other third countries, this is the 
first request of its kind from a Western Balkan country. 
FIgURE 16. The order of priority of the EMCDDA’s work 
with third countries 
Eastern and 
southern neighbours
Candidate and 
potential
candidate countries
Other third
countries
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At the regional level, the cooperation mainly took place in 
the framework of the technical cooperation project for IPA 
beneficiary countries, namely the IPA 6 project. 
In 2018, under this project, the EMCDDA continued to 
consolidate beneficiaries’ capacities to monitor the drug 
situation, applying evidence-based tools and knowledge built 
and promoted within the EU, including on the information 
exchange regarding and monitoring of NPS. 
The project launched the first-ever national GPS on drugs in 
Bosnia and Herzegovina and the results are expected early 
2019. A data-collection exercise on assessing drug seizure 
data in the region was also repeated for the second time in a 
row.
It is also important to highlight the continuous participation of 
the experts from the beneficiaries in various EMCDDA expert 
meetings and the annual meeting with the EU HFPs. 
A new development in cooperation with the beneficiaries was 
the first-ever review of the operationality of the national drug 
observatory and the national early warning system on NPS in 
both Serbia and Montenegro, which was carried out in June 
(see also Key area 2). The assessment and the resulting report, 
with the accompanying recommendations, will hopefully 
contribute to further implementing the actions planned under 
Chapter 24 of the EU acquis. 
Furthermore, the Reitox Academy on ‘New psychoactive 
substances: definition, situation and treatment’ was organised 
in Belgrade on 20 December in collaboration with the Ministry 
of Health of Serbia. This training session was attended by 
25 professionals from the prevention field and staff from the 
Reitox NFPs.
Visibility was increased through the communication of project 
activities via the EMCDDA digital channels and by making 
some EMCDDA flagship products more accessible to the 
national audiences in the beneficiary countries. 
The EMCDDA-IPA 6 mid-term coordination meeting took 
place in Skopje on 18 September, which was attended by six 
National Correspondents. The event allowed the progress 
made over the previous 12 months to be assessed and 
allowed the activities to be planned for the remaining 10 
months of the project. Finally, the EMCDDA organised the 
second EMCDDA-IPA 6 project steering committee meeting in 
November 2018.
FIgURE 17. Implementation of the IPA 6 project 
Overall objective
to ensure that, upon accession, candidate and potential 
candidate countries are able to eectively participate in the 
activities of the EMCDDA and the Reitox network.
Duration
24 months (1 July 2017–30 June 2019) 
Beneciaries
Albania, Bosnia-Herzegovina, North Macedonia, Kosovo*, 
Montenegro and Serbia. 
*is designation is without prejudice to positions on status, and is in line with 
UNSCR 1244/1999 and the ICJ Opinion on the Kosovo declaration of 
independence.
Budget
EUR 340 000
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EU neighbouring countries
Cooperation with neighbouring countries took place mainly 
with those countries with which the EMCDDA has working 
arrangements/MoUs in force, namely with Armenia, Georgia, 
Israel, Moldova and Ukraine. These countries were invited to 
participate at relevant EMCDDA expert meetings and they 
attended the following meetings: Armenia, Georgia, Moldova 
and Ukraine attended the seventh extended Reitox meeting 
(13 November); Georgia attended the GPS, EWS, PDU and 
DRID expert meetings; and Israel attended the 18th meeting of 
the Legal Correspondents of the ELDD.
Furthermore, on 9 March, the EMCDDA submitted to the EC 
a technical proposal for a new technical cooperation project 
for ENP partner countries entitled ‘EU4 Monitoring Drugs’; it is 
to be financed by the ENI. The grant agreement between the 
EC and the EMCDDA was signed in December 2018 and the 
project started on 1 January 2019 (see Figure 18z). 
Other third countries
Since 2017, the EMCDDA has also had a working arrangement 
in place with Switzerland. Within this framework, Swiss 
representatives attended the GPS, EWS, PDU and TDI expert 
meetings, as well as the EMCDDA reference group meeting on 
drug supply reduction. 
In September, an official delegation from the Russian 
Federation visited the EMCDDA. Cooperation is covered by 
the MoU signed between the EMCDDA and the Federal Drug 
Control Service in 2007 and is to continue with the Russian 
Ministry of Interior, which, in 2018, took over the tasks of the 
Federal Drug Control Service.
Finally, the EMCDDA continued to contribute its know-how 
to EU drug-related regional programmes, as requested by 
the EC. This included support to the implementation of the 
new COPOLAD II project and to the CADAP 6 project, which 
are funded by the EC in Latin America and Central Asia, 
respectively. 
The EMCDDA is a full member of the COPOLAD II Steering 
Committee and Permanent Council. In 2018, the agency 
participated in and contributed to the Permanent Council 
meeting organised back-to-back with the COPOLAD annual 
conference in June in Sofia. The EMCDDA also contributed 
to the working groups on the Country Drug Reports, the 
EWS, new threats and problematic drug use. The EMCDDA 
also provided its leading expertise to the preparation and 
production of the EWS guidelines for the COPOLAD project in 
Spanish. The Spanish and English versions are expected to be 
published by COPOLAD in 2019.
Finally, the EMCDDA attended the COPOLAD annual 
conference on precursors in November. The joint EMCDDA and 
COPOLAD report entitled ‘Exploring new and emerging drug 
trends and developments in CELAC countries: joint report 
from the EMCDDA and COPOLAD workshop on trendspotter 
methodology’ was published in November.  
FIgURE 18. EU4 Monitoring Drugs project  
Overall objective
to contribute to improving national and regional responses of 
neighbourhood countries to the security and health threats 
posed by contemporary drugs markets and related issues
Specic objective  
(a) to enhance the capacity of neighbourhood countries to 
rapidly identify, analyse and report eectively on ongoing, 
emerging and future threats; and (b) to enhance regional 
cooperation in the area of drug monitoring among 
neighbourhood countries and 
with EU Member States
Duration
36 months (extendible if there are delays) 
from 1 January 2019
Beneciaries
Algeria, Armenia, Azerbaijan, Belarus, Egypt, Georgia, 
Israel, Jordan, Lebanon, Libya, Moldova, Morocco, 
Palestine*, Tunisia and Ukraine 
* is designation shall not be construed as recognition of a State of 
Palestine and is without prejudice to the individual positions of the Member 
States on this issue.
Budget
EUR 3 million
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 CHAPTER 3
  Management and leadership
I  Corporate area Governance
In 2018, the EMCDDA consolidated the organisational 
measures that were set out in 2017 with a view to ensuring the 
successful implementation of the EMCDDA Strategy 2025. 
A priority for this area was to support the fourth external 
evaluation of the EMCDDA, which was carried out during the 
year by the EC.   
I EMCDDA Director — main activities 
The Director, through his external activities, contributed to 
increasing the visibility of the EMCDDA and consolidating the 
credibility of its work by building and improving partnerships. 
For instance, Mr Goosdeel strengthened relationships with 
the EP. The Director gave presentations at two meetings of 
the Committee for Civil Liberties, JHA (LIBE Committee). He 
was invited for the first time to a meeting of the Committee 
for Environment, Public Health and Food Safety (ENVI 
Committee). This provided the Director with an opportunity 
to inform MEPs on 19 February about ongoing drug-related 
challenges for the EU in the area of public health.
On 4 December, the Director of the EMCDDA participated in a 
high-level panel discussion entitled ‘EU 2019-24: how can we 
support viral hepatitis elimination in line with the WHO Global 
Strategy and UN SDGs?’ at the EP. The event was co-hosted 
by Dr Cristian-Silviu Bușoi, MEP and Chair of the Friends of 
the Liver Group in the EP and Associations Collaborating on 
Hepatitis to Immunize and Eliminate the Viruses in Europe 
(ACHIEVE). 
He had meetings throughout the year with several MEPs who 
were members of the LIBE and ENVI Committees on issues 
concerning the work of the agency.
In April, the Director welcomed a delegation from the Council 
Secretariat at the EMCDDA. The delegation was composed of 
Mr Gilles Duval, Head of the Evaluations in Justice and Home 
Affairs (JHA) and Drugs Policy Unit within the Directorate-
General of Justice and Home Affairs, and Ms Jurga Valanciute 
and Ms Mailys Ramonatxo, both policy administrators. The 
Director was invited on behalf of the Bulgarian Presidency to 
attend the session entitled 'Multidisciplinary approach in the 
area of Internal Security: The EU Policy Cycle for organised and 
serious international crime 2014-2017: policy debate' at the 
JHA Council meeting on 5 June in Luxembourg.
On 5 October, the Director participated in an event at the 
Ministerial Forum of JHA in Tirana (Albania). On this occasion, 
the draft working arrangement between the EMCDDA and the 
Republic of Albania was initialled by the EMCDDA Director, 
the Deputy Minister of Interior (Mira Rakacolli) and the Deputy 
Minister of Health and Social Affairs (Besfort Lamallari). 
Commissioner Avramopoulos witnessed the ceremony.   
The Director was invited on behalf of the Austrian Presidency 
to participate, together with Directors from other JHA agencies, 
in the policy debate on the priorities for the next multi-annual 
financial framework, which was organised at the JHA Council 
meeting in Brussels on 6 December. 
Throughout the year, the Director had regular meetings with 
the EC’s services, including meetings with the Cabinet of 
Commissioner Avramopoulos and the Director-General of 
DG HOME, Paraskevi Michou, and with the Deputy Director-
General, Olivier Onidi. The new Director for Security at DG 
Home, Laurent Muschel, paid a visit to the EMCDDA on 18-19 
October. Several meetings were held with Ms Floriana Sipala, 
Head of the Organised Crime and Drugs Policy Unit at DG 
HOME. 
The 2018 EDR was launched at a press conference in 
Brussels on 7 June by Dimitris Avramopoulos, the European 
Commissioner for Migration, Home Affairs and Citizenship, and 
the EMCDDA Director, Alexis Goosdeel. 
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The Director participated in the TAIEX Forum for Prosecutors 
on Fighting Organised Crime on 3 October in Lisbon, at which 
he gave a presentation on the state of play of drug trafficking, 
smuggling, production and distribution in the EU and its 
neighbouring countries. Two experts from the JRC of the EC 
met with the Director on 12 November before a meeting to 
explore ways to cooperate on the EMCDDA ‘Futures exercise’ 
(see Cross-cutting area B). 
With regard to building relationships with the other EU 
agencies, the Director paid a visit to ECDC in Stockholm on  
23-24 January, together with the Head of the Public Health 
Unit. 
On 13 June, Mr Goosdeel participated in an event in Brussels 
re-launching the EU Agencies’ commitment to working 
together against trafficking in human beings. This event 
was organised by the EU Anti-Trafficking Coordinator and 
in attendance were the Bulgarian Minister of Interior, the 
Director-General of DG HOME and the Directors of the JHA 
Agencies. Mr Goosdeel visited his new counterpart at Europol, 
Ms Catherine De Bolle, in the first official meeting between the 
two heads of agencies on 17 July. The Director participated in 
the meeting of JHA Agencies in Vilnius on 23 November.
The Director signed a working arrangement between the 
EMCDDA and three EU Agencies, further to Regulation EU 
2017/2101 on the EWS on NPS. The other signatories were 
the Executive Director of ECDC, who signed in Brussels on 4 
December, the Executive Director of Europol, who signed in 
Brussels on 6 December, and the Executive Director of EMA, 
who signed in London on 7 December.
The Director participated in the Special Segment of the 61st 
session of the Commission on Narcotic Drugs in March. 
He also addressed the third inter-sessional meeting of the 
Commission on Narcotic Drugs on 25 September nominated 
by the EU and speaking for the Western European and 
Others Group (WEOG) at the UN. Mr Goosdeel placed special 
emphasis on the role of evidence in the development of 
European drug policy and on the sharing of best practice. Both 
events were organised by the UNODC in Vienna. 
Mr Goosdeel participated in the first European ‘Forum 
Addictions & Société’ organised by the Brussels Federation 
of Institutions for Drug Addicts (FEDITO) on 16-17 October 
in Brussels. On the occasion of the official visit to Portugal 
of Their Majesties the King and Queen of the Belgians, the 
Director received a request from the Minister-President of 
Brussels-Capital, Mr Rudi Vervoort, to visit the EMCDDA on 
24 October. On 15 November, the Director made a keynote 
speech in the opening plenary session at the NIGHTS2018 
conference in Brussels, focusing on many topics related with 
nightlife.  
The Director paid an official visit to Germany on 1 October 
at the invitation of the Federal Drug Commissioner Marlene 
Mortler. Discussions centred on the further development of 
cooperation between Germany and the EMCDDA and the 
agency’s work priorities as outlined in Strategy 2025 and the 
Programming document 2018–20.
The Director also paid official visits to Estonia, France, Cyprus 
and Lithuania. He had a meeting in Paris with the Chair of the 
Management Board and the President of Mildeca (Mission 
interministérielle de lutte contre les drogues et les conduites 
addictives), Mr Nicolas Prisse. On the same day, he had a 
meeting with the head of the French NFP, Mr Julien Morel 
d’Arleux and presented the recent EMCDDA publication 
Medical use of cannabis and cannabinoids: questions and 
answers for policymaking to national policymakers.
During a visit to Greece on 9 and 11-12 October, the Director 
gave lectures on 9 October at Athens University and on 11 
October at the Aristotle University in Thessaloniki. He also 
visited KETHEA’s Ithaki Community in Thessaloniki and 
participated in a workshop at the Aristotle University with 
practitioners from treatment centres. The Director made an 
opening address at the ninth conference of the EUSPR on 24 
October in Lisbon.
Mr Goosdeel participated in several events organised by 
the Portuguese authorities, had bilateral meetings with EU 
Member State ambassadors and attended a number of 
receptions held to mark national days at the embassies of 
various EU and non-EU countries. 
The Director met with the new Executive Secretary of the 
Pompidou Group of the Council of Europe, Mr Denis Huber, on 
12 September and participated in the Ministerial Conference 
The Heads of EASO, Europol, eu-LISA, the EMCDDA, Eurojust, EIGE, 
Frontex, FRA, CEPOL, and Eurofound signed a Joint Statement of 
commitment to working together to address trafficking in human beings, 
ensuring a coordinated, coherent and comprehensive response.
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of the Pompidou Group on 27-28 November in Stavanger, 
Norway.
The Director and the Scientific Director of the EMCDDA paid 
a visit to the United States (Washington, DC, and Denver) 
on 5-9 February. The purpose of this visit was to allow the 
senior members of the EMCDDA to be informed about the 
developments occurring in the United States related with the 
mandate of the EMCDDA. The visit in Washington included 
meetings with relevant US scientific partners, such as the 
Director of the National Institute of Drug Abuse (NIH/NIDA). 
In Denver, the EMCDDA representatives discussed recent 
developments around cannabis policies with Government 
officials from the State of Colorado and with researchers 
working in the field. 
The Director participated on 29 November in an International 
Conference on ‘Drugs and Addictions: An Obstacle to 
Integral Human Development’ organised by the Dicastery 
for Promoting Integral Human Development at the Vatican 
City in Rome. Mr Goosdeel spoke during a round table on 
‘Production, trafficking and consumption of drugs: the situation 
in the various regions of the world’. His presentation focused 
on recent trends and developments and future challenges 
in the European drug situation and the EMCDDA’s mission 
to contribute to a healthier and more secure Europe. The 
conference was a direct response to the Pope’s call for 
resolve in the fight against drugs and an expression of the 
commitment of the Church to addressing the problem.
I The external evaluation of the EMCDDA
The fourth external evaluation of the EMCDDA was carried out 
by the EC with support from an external consultant. The final 
report of the external contractor, which was presented by the 
EC at the Management Board meeting in December, contained 
some very positive results for the EMCDDA. According to the 
report, the agency is performing very well, delivers excellent 
outputs and has a high reputation at the European and 
international levels. Some recommendations for improvements 
were put forward by the consultants, in particular concerning 
a number of issues that could be implemented within 
the current legal framework, such as improvements to 
the dissemination of EMCDDA outputs, human resources 
management and activity-based management. Some of the 
other recommendations focused on different aspects, such as 
enhancing the EMCDDA’s capacity to monitor drug supply-side 
issues, focusing international cooperation activities on adding 
value to EMCDDA core objectives and broadening the scope of 
the mandate to other types of addictions.
The Commission report, which presents the main conclusions 
of the evaluation, was prepared by the EC and adopted on 14 
May 2019.
I Strengthening the organisational structure and   culture
Work carried out during 2017 on the EMCDDA organisational 
structure continued in 2018, when further adjustments and 
fine tuning were implemented with the support of an external 
consultant. This process aimed to ensure that:
  the mission statements and the key tasks of all units of 
the EMCDDA organisational structure were reviewed and 
aligned to the EMCDDA Strategy 2025;
  the EMCDDA key operating processes were identified;
  job roles were clearly defined and translated into staff job 
descriptions, with the aim of producing dynamic, proactive 
and service-oriented profiles.
Ultimately, this will help to achieve better consistency in the 
definition of roles, tasks and responsibilities over the whole 
organisation; to increase employees’ job satisfaction and 
engagement overall; and to transform the EMCDDA into 
a more dynamic, highly performing and service-oriented 
organisation, in line with the values and long-term goals of the 
EMCDDA Strategy 2025. 
I Strategic planning, performance monitoring and   reporting
The year 2018 saw the adoption by the EMCDDA Management 
Board of the PD 2019-21, the EMCDDA’s first PD fully 
aligned with the EMCDDA Strategy 2025, and thus this was 
a cornerstone in the strategic planning work of the agency. 
On the same day, the Management Board also adopted 
the Preliminary Draft PD 2020-22, which, in line with the 
EMCDDA’s Financial Regulation, was subsequently submitted 
to the EC for formal consultation on 31 January 2019. 
The successful implementation of the EMCDDA Strategy 2025 
depends on the optimal performance of the agency, both 
substantive (effectiveness) and operational (efficiency). 
To increase its efficiency, the agency is pursuing the 
development and adoption of a unified corporate project 
management methodology for its applicable activities. To that 
end, the methodology chosen was PM2 (Project Management 
Squared), which is widely used by the EC and increasingly 
used by agencies; therefore, it ensures that the EMCDDA’s 
work practices are aligned with those of other EU bodies. The 
new project (PM2@EMCDDA) was launched in 2018 and 
implemented throughout the year, with support from an 
external consultant (DG Informatics). Under the umbrella 
of the broader EMCDDA Project Management Programme 
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initiative, PM2@EMCDDA will be integrated with Matrix@
EMCDDA, the related management information system 
project (see the section in Chapter 4 entitled ‘Information and 
communication technology’). In 2018, 51 staff members were 
trained in the PM2 methodology (i.e. 50 % of all staff), out of 
which nine were PM2 certified.
Another key development was the review of the EMCDDA’s 
performance model, which is presented in detail in the 
PD 2019-21. The process benefited from an exchange of 
experience with Eurofound, an EU agency similar to the 
EMCDDA in terms of its mandate and the size of its operations. 
The new model (see Figure 19), which follows the ‘theory of 
change’ approach, identifies a limited number (10) of key 
performance indicators (KPIs) that will be used to measure 
the effectiveness in delivering the desired outputs and the 
efficiency in using the resources allocated to that end. They 
are complemented by higher level KPIs, at the outcome and 
impact levels. To measure the 10 composite KPIs, smaller 
and more specific performance indicators and additional 
performance data (metrics) are being put in place. 
To pursue performance measurement, an internal 
management plan was put in place to support the detailed 
planning of activities that were defined in the 2018 work 
programme. This internal planning instrument served as the 
basis for the two corporate monitoring exercises that were 
carried out during the year, namely the mid-year monitoring 
and the end-year monitoring, which helped prepare this  
2018 General Report of Activities. 
In terms of corporate reporting, the main output was the 
General Report of Activities for 2017, adopted by the 
Management Board through written procedure and published 
on 15 June 2018. This comprehensive report was forwarded to 
the EP, the Council of the EU, the European Court of Auditors 
and the Internal Audit Service of the EC, in line with the 
provisions of the EMCDDA Founding Regulation. 
I Data protection activities 
In 2018, the new General Data Protection Regulation (EU) 
2016/679 entered into force. Subsequently, information was 
provided and online training materials were disseminated to 
the staff by the EMCDDA data protection officer. Follow-up 
actions have been initiated and emails have been sent to data 
controllers to ensure smooth compliance with the new rules.
FIgURE 19. The new EMCDDA performance model
4
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 CHAPTER 4
  Supporting the achievement of results
The overall objective in this area in 2018 was to ensure that 
the implementation of the activities planned across the 
different areas of the annual work programme were supported 
by effective management of the available resources and by 
efficient ICT services. 
I  Financial and budget management  and accounting
The priorities in the field of financial resources management 
were effective and timely planning, monitoring and execution 
of the EMCDDA budget, and optimising all of the related 
processes. 
These were complemented by the efficient use of material 
resources. 
In this context, the EMCDDA once again achieved an 
outstanding performance in terms of budget execution, with 
99.98 % of commitment appropriations executed (see  
Table 4). In terms of the procurement execution, the 
procurement plan was put in place and successfully executed 
in close collaboration with all units. 
The EMCDDA also participated, as an active member, in the 
annual meeting of the Network of Agencies Procurement 
Officers. 
I  Human resources
The sound management of existing processes, as required by 
the applicable staff regulations and their implementing rules, 
remained key in 2018. 
Another priority was the organisation of appropriate training 
for the agency’s staff, to support the effective implementation 
of the EMCDDA’s new long-term strategy and subsequent 
internal reorganisation (see the section in Chapter 3 entitled 
‘Corporate area Governance’). The target of providing an 
average of three training days per staff member (KPI ADM.1.3,  
see Annex 4) was overachieved (see Table 5). 
An important activity in 2018 was the undertaking of the 
EMCDDA staff engagement survey. The study was opened to 
all staff of the agency, who were asked to give their opinion on 
several aspects of the functioning of the EMCDDA, including 
organisation, cooperation and communication, management 
and leadership, and working conditions. The results were 
presented by the Director at a general staff assembly in 
December 2018. This will be followed by the definition of a 
set of measures aiming to further increase the satisfaction, 
motivation and engagement of the EMCDDA staff.    
Finally, as in previous years, the EMCDDA played an active role 
in discussions held by several inter-agency working groups in 
this area. 
TAblE 4. Budget execution
Commitment appropriations 99.98 % 
Payment appropriations 98.02 %
Consumption of 2018 (C8) credits 94.20 %
TAblE 5. Training provided
Total number of training days 521
Training days per staff member (average) 5
Budget spent on training (EUR) 85 413 
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I  Infrastructure and logistics
In the area of logistics and infrastructure management, 
ensuring a healthy and safe working environment remained 
the key priority in 2018. Further measures to reduce the costs 
of utilities were implemented during the year, which led to 
achieving an overall reduction of 3 %. In 2018, a reduction of 
3.84 % in utility costs was achieved compared to 2017.
The ‘carbon footprint’ of the agency was calculated in the 
yearly environmental report and, as regards utilities (water, gas, 
electricity), CO
2
 production had decreased by 36.8 % (8).
The identification of health and safety risks for staff remained 
one of the main priorities of the agency, as did increasing 
effectiveness, efficiency gains and cost savings, including 
through further synergies with the European Maritime Safety 
Agency. 
The information included in the risk registry was adapted 
following the annual risk assessment exercise that was 
delivered in 2018. 
The internal environmental policy of the EMCDDA was further 
implemented and an environmental report was delivered in 
2018. The agency also continued to contribute to the inter-
agency Greening Network. 
I  Information and communication technology
The EMCDDA’s ICT programmes and services are developed 
and delivered in line with the triennial objectives, which are 
to implement and support core business and corporate 
projects and processes and to provide a continuously stable 
environment that supports existing basic and advanced 
services. 
Concerning providing support to core business areas, in 
2018, the priority was to maintain and develop the EMCDDA’s 
established online data collection platforms, namely Fonte, 
EDND and the Drugs Data Warehouse. The development of 
the EDND continued as a major line of work in order to ensure 
the inclusion of advanced technical functionalities. The new 
database will allow electronic and secure submission of data 
from the EWS national correspondents, being adapted to the 
new applicable legal framework.
Support was also provided to corporate areas, particularly 
planning and performance monitoring activities, namely for 
the development of the corporate management information 
system, which is now part of the EMCDDA’s new Project 
Management Programme initiative (see the section in Chapter 
3 entitled ‘Corporate area Governance’), as well as human 
resources and financial management processes. The optimal 
allocation and prioritisation of ICT resources was supported by 
the internal ICT Steering Committee, by refining priorities and 
deciding on the intensity of work to be devoted to each activity, 
depending on the most critical organisational needs.
(8) The 2018 environmental report was based on data collected in 2017.
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 CHAPTER 1
 Management Board’s analysis  
  and assessment
The Management Board has analysed and assessed the 
Authorising Officer’s (Director’s) General Report of Activities 
for the financial year 2018.
The Management Board appreciates the performance of the 
Centre in implementing its work programme and welcomes, in 
particular, the final report of the EMCDDA’s external evaluation 
presented by the EC at the Management Board meeting in 
December 2018, which contained some very positive results 
for the EMCDDA. 
In assessing the report, the Management Board wished to 
highlight the following achievements: 
  The EMCDDA presented its annual overview of the 
European drug situation — the EDR package. The agency 
published in total 45 outputs, including a report entitled 
Medical use of cannabis and cannabinoids: questions 
and answers for policymaking, which was published as 
a response to growing interest in the development of 
policies and practice in this area. In addition, 30 Country 
Drug Reports were released together with the EDR 
package.
  In terms of support to policy, the EMCDDA continued to 
support drug policy dialogue at the EU and national levels 
and was very active in providing support to the EC and the 
External Action Service on activities with third countries. 
The agency attended close to 60 key EU and international 
drug policy and institutional events. The EMCDDA 
successfully chaired the EU-ANSA network in 2018.
  The EMCDDA maintained close communication with the 
EU Member States, in particular with the Reitox network 
of NFPs, and undertook various technical or institutional 
missions in Member States. The Director paid high-level 
institutional visits to five Member States.
  In 2018, the EMCDDA continued to play a leading role in 
ensuring the continuous and robust implementation of the 
EU EWS on NPS. Until 23 November, this was carried out 
under the terms of Council Decision 2005/387/JHA on 
the information exchange, risk assessment and control of 
NPS, after which the new legal framework on NPS started 
being applied. Three new working arrangements were 
concluded, with Europol, ECDC and EMA, with a view to 
implementing the new NPS legislation. Two more similar 
working arrangements were prepared with ECHA and 
EFSA, which were signed in February 2019.
  In the area of monitoring new trends in the drug situation, 
the EMCDDA made further progress on developing novel 
data sources, including web surveys on drugs, wastewater-
based epidemiology and hospital emergencies data. 
  In terms of cooperation with third countries, the agency 
successfully carried on implementing the IPA 6 project, 
which was launched in 2017. The EMCDDA signed a grant 
agreement with the EC for a new technical cooperation 
project for ENP partner countries, entitled ‘EU4 Monitoring 
Drugs’. It will be financed by the ENI, beginning on  
1 January 2019.
  The Management Board welcomed the consolidation of 
the organisational measures that were initiated in the 
previous year, with a view to ensuring the successful 
implementation of the EMCDDA Strategy 2025. It adopted 
the PD for the period 2019-21, the first EMCDDA PD to be 
fully aligned with the EMCDDA Strategy 2025.
  The agency further improved its operational efficiency 
with a high level of implementation of the 2018 work 
programme and it achieved an outstanding performance 
in terms of budget execution, with 99.98 % of commitment 
appropriations executed.
In conclusion, the Management Board welcomes the 2018 
General Report of Activities, which provides an excellent 
overview of the agency’s achievements as set out in the work 
programme adopted by the Board. 
2
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 CHAPTER 2
  Management
I  Management Board — main decisions
As usual, the Management Board met twice during the year. 
The first meeting took place on 28-29 June and the second 
took place on 13-14 December. 
At the June meeting, the Director presented the highlights of 
the EMCDDA’s budgetary and financial performance, as well 
as the main achievements of the EMCDDA in 2017 based on 
the General Report of Activities. The Management Board gave 
a favourable opinion on the EMCDDA’s final annual accounts 
for 2017 and congratulated the Director and his staff on the 
excellent level of budgetary execution. 
The Management Board agreed on the publication of a call 
for expression of interest in membership of the Scientific 
Committee for the mandate 2020-22 and to use the results 
of this call to appoint the new members of the Scientific 
Committee and to establish a new reserve list. Mr Stelios 
Sergides (Cyprus) was elected as Budget Committee member 
by the Management Board for a mandate from 1 July 2018 to 
30 June 2021. 
The Management Board mandated the Director to negotiate a 
working arrangement between the EMCDDA and the Republic 
of Albania, with both the Ministry of Interior and the Ministry of 
Health and Social Protection of Albania. 
The meeting included an exchange of views about the 
challenges and perspectives for the implementation of best 
practice in demand-reduction interventions in Europe. After 
a presentation by the EMCDDA, the Chair invited several 
Member States to present examples of innovative experience 
at the national level.
The EC updated the Management Board members on the 
external evaluation of the EMCDDA. The Director shared with 
the Management Board members two key documents that 
had been sent to the external evaluators, namely the EMCDDA 
‘Theory of change’ and the ‘Intervention logic’.
The Director updated the Management Board on the state 
of implementation of the recommendations issued by the 
Internal Audit Service (IAS) of the EC from 2015 onwards. 
The Director informed the Management Board about the 
‘EU4 Monitoring Drugs’ project, which will cover Eastern and 
Southern neighbours and their neighbouring countries and will 
allow the EMCDDA to identify, analyse and report effectively 
on ongoing, emerging and future trends in the drug market and 
their implications for security and health. The project started 
at the beginning of 2019. The total estimated EU financing 
for this project should amount to about EUR 3 million for the 
whole period and the first part of the revenue will be entered 
into the EMCDDA draft budget for 2019 (about EUR 1 million).
The draft working arrangements with five EU agencies (Europol, 
EMA, EFSA, ECDC and ECHA) to implement Regulation EU 
2017/2101 of the European Parliament and of the Council of 
15 November 2017 about the EWS on NPS were adopted by 
written procedure by the Management Board on 9 November. 
On the basis of the recommendation of the Budget Committee 
and the Executive Committee, the Management Board 
adopted amending budget No 1 to the 2018 EMCDDA budget 
on 29 November. 
At its 58th meeting, on 13-14 December, the Management 
Board conducted an initial discussion on the external 
evaluation of the EMCDDA, which was run by the EC (DG 
HOME) in 2018 with the support of an external contractor. The 
evaluation aimed both to assess the relevance, effectiveness, 
efficiency, coherence and added value of the agency’s 
performance since 2013 and to propose concrete and 
useful recommendations that may lead to the revision of the 
agency’s mandate, should this be deemed necessary, to allow 
the agency to better respond to the challenges posed by a 
constantly changing environment. The Chair and the Vice-Chair 
represented the Management Board in the ad hoc group for 
the external evaluation. The EC presented the key findings and 
recommendations of the external evaluation of the EMCDDA, 
which were circulated two weeks ahead of the meeting, and 
outlined the next steps. The Management Board members 
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exchanged views on the future of the agency, based on the 
recommendations of the final report.  
The EC provided an update on the negotiations for the 
Multi-annual Financial Framework for 2021-27. In line with 
the provisions of Article 32 of the Framework Financial 
Regulation applicable to EU agencies and of the EMCDDA 
Financial Regulation, the Management Board adopted the 
EMCDDA’s PD for the period 2019-21, including the 2019 
work programme, on which the EC and the EMCDDA Scientific 
Committee had given favourable opinions. The Board also 
adopted the EMCDDA’s preliminary draft PD for 2020-22, 
which includes the preliminary draft work programme for 2020. 
As usual, at the December meeting, the Management Board 
adopted the EMCDDA’s 2019 budget. The budget for 2019 
attributes EUR 15 286 600 as the main revenue to be 
provided by the EU 2019 subsidy to the EMCDDA, EUR 407 
997.32 for the contribution by Norway and EUR 273 703.63 
for the contribution by Turkey for its participation in the work 
of the EMCDDA. The Management Board also adopted the 
preliminary draft budget for 2020.
The Management Board elected Ms Laura d’Arrigo (France) 
and Mr Franz Pietsch (Austria) for a second mandate as Chair 
and Vice-Chair of the Management Board, respectively, from 
1 January 2019 to 31 December 2021. Mr Lars Petersen 
(Denmark) was elected as a member of the Executive 
Committee from 1 January 2019 to 31 December 2021. The 
Management Board also elected Mr Claude Gillard (Belgium) 
as a Budget Committee member for a mandate from 1 January 
2019 to 31 December 2021. The Management Board also 
unanimously elected Mr Claude Gillard as Chair of the Budget 
Committee for the same period.
The Management Board agreed with the working arrangement 
between the EMCDDA and the Ministry of Interior and Ministry 
of Health and Social Protection of the Republic of Albania, and 
mandated the Director to sign the working arrangement on a 
date and place to be jointly decided.
The Management Board mandated the Director to negotiate a 
working arrangement with the Ministry of Health of Ukraine. 
As proposed by the Executive Committee, the Management 
Board designated as the reporting officers of the EMCDDA 
Director the newly elected Vice-Chairperson of the EMCDDA 
Management Board and Mr Olivier Onidi, the representative 
of the EC in the Board. The Management Board further 
designated as the appeal assessor the newly elected 
Chairperson of the EMCDDA Management Board.
The Management Board adopted the proposed revision of its 
Rules of Procedure to align them with the new Regulation 
EU 2017/2101 of the European Parliament and of the 
Council of 15 November 2017 about the EWS on NPS. The 
Board confirmed, and extended until 31 December 2019, 
the validity of the last panel of experts for the ‘extended’ 
EMCDDA Scientific Committee that was set up in accordance 
with Article 6.2 of Council Decision 2005/387/JHA. The 
Management Board endorsed the draft call for expression of 
interest for the implementation of the procedure established 
for the ‘extended’ Scientific Committee, as well as the call 
for expression of interest in membership of the EMCDDA 
Scientific Committee for the mandate 2020-22. 
After the presentation of the EMCDDA report on the medical 
use of cannabis and cannabinoids and other recent cannabis-
related outputs, the Management Board discussed the latest 
developments in cannabis policies for a better-informed 
debate. The Chair invited some delegations to briefly share 
recent experiences. 
The Director updated the Management Board on the 
implementation of the EMCDDA Strategy 2025 and on the 
state of play concerning the outstanding recommendations of 
the IAS of the EC.
Portugal provided information about the third European 
Addiction Conference, which will take place in Lisbon on 23-25 
October 2019, organised by the Portuguese SICAD (Serviço de 
Intervenção em Comportamentos Aditivos e Dependências — 
General Directorate for Intervention on Addictive Behaviours 
and Dependencies), the journal Addiction (of the Society for 
the Study of Addiction), the EMCDDA and the International 
Society of Addiction Journal Editors (ISAJE).
I  Executive Committee —  main decisions
In 2018, the Executive Committee met four times in Lisbon  
(18 May, 28 June, 26 October and 12 December). 
On 18 May, the Executive Committee adopted, on behalf of 
the Management Board, general provisions for giving effect 
to the Staff Regulations on learning and development. At its 
meetings of 18 May and 28 June, the Executive Committee 
reviewed the items of the draft agenda of the Management 
Board meeting of 28-29 June 2018 and proposed some 
modifications to draft documents. 
At its meeting of 28 June, the Executive Committee adopted, 
on behalf of the Management Board, general provisions 
for giving effect to the Staff Regulations on the temporary 
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occupation of management posts and on the guide to 
missions and authorised travel.
On 26 October, the Executive Committee prepared for the 
Management Board meeting of 13-14 December 2018. On 
the basis of the recommendation of the Budget Committee, 
the Executive Committee agreed that the Chair should launch 
a written procedure for the adoption of amending budget 
No 1 to the 2018 EMCDDA budget by the Management 
Board. The Executive Committee adopted, on behalf of the 
Management Board, general provisions for giving effect to the 
Staff Regulations on middle management and the function of 
advisers.
On 12 December, the Executive Committee passed in review 
the items of the draft agenda of the Management Board 
meeting of 13-14 December 2018. The Executive Committee 
also adopted, on behalf of the Management Board, general 
provisions for giving effect to the Staff Regulations on outside 
activities and assignments and on occupational activities after 
leaving the service. 
At the beginning of each meeting of the Executive 
Committee, the Chair of the Budget Committee reported on 
the conclusions of the meetings held prior to the Executive 
Committee meetings and on the recommendations made by 
the Budget Committee.
I  Budgetary and financial management
I Information in the report on budgetary and  financial management (Article 93 of the  Framework Financial Regulation)
Information on budgetary and financial management is 
covered by the report included in the EMCDDA’s Annual 
accounts 2018.
In terms of procurement execution, the procurement plan was 
put in place, in line with the EMCDDA 2018 management plan, 
and successfully executed in close collaboration with all units. 
The negotiated procedures launched during the course of the 
year are outlined in Table 6.  
I Summary of budgetary operations, revenue and        expenditure
The information about the appropriations transferred in 
2018 can be found in the report on budgetary and financial 
management, as included in the EMCDDA’s Annual accounts 
2018. The EMCDDA Management Board approved one 
amending budget in 2018, which was duly published.   
The main financial/performance indicators for 2018 are 
99.98 % execution of commitment appropriations, 98.02 % 
implementation of payment appropriations, 94.20 % execution 
of appropriations carried forward from 2017 and 0.16 % for 
cancelled/non-used payment appropriations.
TAblE 6. EMCDDA tenders in 2018
Tendering 2018 figures Number of direct contracts 
Number of 
framework contracts 
Negotiated procedures — disp. Article 134 — Rules of implementation 
of the Financial Regulation (exceptional procedures) 
1 1 0
Negotiated procedure — single tender* 103 103 0
Negotiated procedure — at least three candidates 11 9 2
Negotiated procedure — at least five candidates 2 2 0
Open procedures 2 1 1
EC frameworks joined 0 0 0
* Including appointment letters and very low-value contracts.
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I  Human resources management
I Human resources developments
The work to align the EMCDDA’s human resources processes 
and policies with the reform of the EU Staff Regulations 
continued in 2018. This included, in particular, the adoption of 
implementing rules on the learning and development strategy 
package (Decision C(2016)3828), the temporary occupation of 
management posts (DEC/MB/2018/03), middle management 
staff (DEC/MB/2018/09) and the function of advisers  
(DEC/MB/2018/10). 
As in previous years, the EMCDDA played an active role in 
discussions held by several inter-agency working groups in  
this area. 
As regards the EMCDDA 2018 establishment plan, there was 
one authorised post less than in the EMCDDA establishment 
plan for 2017 (i.e. 77 and 76 posts, respectively), pursuant to 
the relevant decision of the EU budget authority.
I Brief description of the results of the screening/  benchmarking exercise
The results of the EMCDDA 2018 staff screening exercise 
reflect the EMCDDA’s efforts to ensure the effective and 
efficient allocation and use of its resources. The results show 
that 72.95 % of the EMCDDA’s human resources capacity 
was devoted to operational activities in 2018 and only 17.53 
% was allocated to administrative support and coordination; 
the remaining 9.52 % was assigned to operations considered 
neutral (see Annex 2). 
I Assessment by management
The EMCDDA has set its internal procedures for budget 
execution and internal control, while defining and 
implementing a partially decentralised management model, 
in accordance with the EMCDDA Financial Regulation, which 
integrally transposes the text of European Commission 
Delegated Regulation (EU) No 1271/2013 on the Framework 
Financial Regulation for EU agencies. 
As a consequence, both the operational and the financial 
decisions required for the implementation of the EMCDDA’s 
work programme and budget have been delegated to the 
heads of unit. The administration unit provides support to 
managers for budgetary and financial management execution 
and implementation of financial transactions, as well as for 
internal planning, monitoring and reporting. 
These procedures have been codified and all of the EMCDDA’s 
deputy authorising officers have received specific training and 
information on their roles, duties and liabilities, in accordance 
with the provisions of financial and staff regulations. 
The key actors and steps of the EMCDDA procedures for 
budget execution can be summarised as follows (see also 
Tables 8 and 9 below): 
  Project manager: initiates and provides operational input 
for the administrative and financial operations related to 
project implementation (e.g. technical specifications for 
procurement procedures, cost estimates and ‘certified 
correct’ for payments). 
TAblE 7. EMCDDA negotiated procedures in 2018
Works Supplies Services Total for 2018
Number 
of 
contracts
Volume of 
contracts 
(EUR)
Number  
of 
contracts
Volume of 
contracts 
(EUR)
Number 
of 
contracts
Volume of 
contracts 
(EUR)
Number 
of 
contracts
%
Volume of 
contracts 
(EUR)
%
EUR > 1 000 
and ≤ 15 000
7 20 088.22 18 58 130.61 78 464 582.72 103 88.03 542 801.55 49.54
EUR > 15 000 
and ≤ 60 000
0 0.00 2 70 000.00 10 238 939.00 12 10.26 308 939.00 28.19
EUR > 60 000 
and ≤ 144 000
0 0.00 0 0.00 2 244 000.00 2 1.71 244 000.00 22.27
Total 7 20 088.22 20 128 130.61 90 947 521.72 117 100 1 095 740.55 100
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  Financial management team: financial and contractual 
support officers provide assistance in the preparation of 
administrative and contract documents with the input of 
the project manager involved. 
  Budget planning and monitoring: budget officer checks for 
consistency with work programme and budget allocations. 
  Financial management: initiating officers carry out 
operations using the EMCDDA’s electronic management 
and accounting system (ABAC), prior to decisions of the 
Authorising Officer. 
  Executive office unit: the verifying officer carries out ex 
ante financial checks. 
  Head of unit or Scientific Director: gives authorisation 
for budgetary and legal operations and acts as deputy 
authorising officer by delegation (by the Director as the 
EMCDDA Authorising Officer) for the execution of the 
tasks/activities of his/her unit, within the limits of the 
adopted EMCDDA annual work programme and budget. 
  Accounting officer: executes and records payments and 
recovery orders. 
The procedures presented above are consistent with the 
EMCDDA’s project-based working methods, which aim to 
integrate activity and resource management, in accordance 
with activity-based management/activity-based budgeting 
principles. In this context, the EMCDDA established 
procedures for planning, monitoring and reporting, with a 
clear indication of the actors involved, their roles and their 
responsibilities. 
After the adoption of the new ‘Operating framework for the 
Reitox system’ in January 2003, a new grant agreement model 
was introduced for the annual co-financing of activities by the 
Reitox NFPs. This agreement requires that an external audit 
is carried out each year by an independent body or expert, 
in order to certify that any financial documents submitted 
to the EMCDDA comply with the financial provisions of the 
agreement, that the costs declared are the actual costs and 
that all receipts have been declared. 
TAblE 8. Key features of the EMCDDA’s partially 
decentralised management mode
Level of operations  
(and actors) Role/operations
Decentralised level 
(operational and 
technical units) 
Operational initiative/input and operational 
and financial decisions by delegation in 
order to implement the work programme 
and budget 
Central level 
(Executive office unit 
and Administration 
unit) 
Coordination and management 
of executive planning, monitoring, 
reporting and assessment of the 
implementation of the work programme 
and budget. Administrative and financial 
support, management and control of 
implementation 
TAblE 9. Key actors involved in the implementation of the EMCDDA’s partially decentralised management model
Level of operations Actors Role/operations
Decentralised level 
(operational and 
technical units) 
Project manager and Head of 
the unit concerned 
Initiates and provides operational input to the operations required to implement 
projects 
Central level 
(Administration unit) 
budget planning and 
monitoring team 
Checks the consistency of operations with the adopted work programme and 
budget. budgetary appropriations to be committed are set aside 
Human resources 
management team 
Defines rights and checks compliance with staff regulations for staff-related 
management and expenditure 
Financial management team 
Prepares the required administrative and legal supporting documents and 
controls compliance with applicable regulations, and processes the required 
financial operations 
Central level (Executive 
office unit) 
Verifying officer Ex ante verification 
Decentralised level 
(operational and 
technical units) 
Head of unit/deputy 
authorising officer 
Authorises budgetary and legal commitments and payments 
Central level 
(Administration unit) 
Accounting officer Executes and records payments and recovery orders 
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The EMCDDA’s activities and operations are scrutinised by 
several processes and actors: 
  external audits by the European Court of Auditors  
(twice a year); 
  external audits for specific projects  
(IPA-funded projects, etc.); 
  discharges by the EP (once a year); 
  internal audits by the IAS of the EC (once a year); 
  opinions of the EC’s services on the agency’s PD  
(once a year); 
  external periodical evaluations (set as every six years in 
the EMCDDA Founding Regulation); 
  agreements by the EC on implementing rules for Staff 
Regulations (one agreement for each rule); 
  consent by the EC on the possible deviation of the 
EMCDDA Financial Regulation from the EC’s Framework 
Financial Regulation for decentralised agencies; 
  the European Data Protection Supervisor for compliance 
with Regulation 45/2001 (by prior notification and upon 
complaint); 
  the European Anti-Fraud Office (upon complaint); 
  the Ombudsman (upon complaint); 
  the European Court of Justice (upon complaint). 
Ex ante controls of financial transactions were applied 
exhaustively throughout 2018 to verify their compliance with 
the EMCDDA Financial Regulation and the corresponding 
implementing rules. These controls were carried out swiftly to 
ensure that payment deadlines were met, legal commitments 
were concluded in a timely manner and income was recovered 
promptly, without prejudice to the application of corrections,  
if required. 
Financial workflows were properly defined and a sound system 
of authorisation of access to the ABAC system was put in 
place. The manual of procedures was applied and updated,  
as required.
I Assessment of audit results during 2018   and the follow-up of audit plans, audits  and recommendations
In 2018, following up on observations and recommendations 
expressed by the European Court of Auditors (ECA), the EU 
Budget Authority and the IAS, the EMCDDA implemented 
measures to further improve its management and internal 
control systems, as outlined below. 
I Internal Audit Service
The last recommendation emerging from the 2013 IAS audit on 
‘Budget and Monitoring’ reached full implementation in 2018; 
that recommendation concerned the need for continuous, 
coherent and reliable information on the achievement of 
planned results at the EMCDDA, with a view to rendering 
the activity-based budgeting (ABB) system fully effective as 
a management tool. All of the necessary actions have been 
taken as they were planned and have been accomplished in 
2018. This recommendation was therefore sent to the IAS for 
review.
Clear progress has been made regarding the implementation 
of the recommendations arising from the 2015 IAS audit on IT 
project management: 
  Three out of the five recommendations still outstanding 
at the end of 2017 (one relating to the setting up of an 
enterprise architecture management framework and two 
others relating to the definition, adoption and automation 
of an IT project management methodology) reached their 
final phases of implementation. They were consequently 
sent to the IAS for review in December 2018. 
  At the end of 2018, only two recommendations — 
relating to the definition and adoption of a requirements 
management process and to the definition and adoption 
of a systems development methodology — were 
still outstanding. Progress in implementing these 
recommendations has been achieved throughout 2018 
and it is expected that they will be implemented by mid-
2019. 
Concerning the 2017 IAS audit on ‘Management of Data 
Collection, Validation and Quality Assurance in the EMCDDA’, 
substantial progress has been made throughout 2018 
regarding the implementation of the two recommendations 
issued by the internal auditors. 
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These concern (1) the performance of a comprehensive 
business needs analysis aimed at identifying current and 
emerging needs and related IT functionalities to support 
data collection, validation and quality assurance processes 
and (2) the review and improvement of the EMCDDA data 
quality management framework. It is expected that these 
two recommendations will be implemented by mid-2019, as 
provided for in the relevant action plan. 
In 2018, the IAS carried out an audit on ‘Publications 
Management in the EMCDDA’, as set out in its 2016-18 
Strategic Internal Audit Plan. An advance version of the draft 
audit report was issued by the IAS in December 2018. This 
report contains three recommendations, all rated by the 
internal auditor as ‘Important’. These three recommendations 
are summarised below:
Recommendation No 1: The EMCDDA should develop and 
adopt a framework for a systematic collection and assessment 
of stakeholders’ feedback concerning its publications. The 
framework should define: (1) the methods and tools to be 
applied; (2) the decision-making process when assessing 
feedback and how lessons learnt are to be incorporated 
into the EMCDDA publications; and (3) the audit-trail of the 
underlying controls. 
Recommendation No 2: Establishment of comprehensive rules 
on assessment of product feasibility and of decision-making 
arrangements for publications not detailed in the annual work 
programme.
Recommendation No 3: The EMCDDA should: (1) where 
necessary, adapt the main workflows, managed by both the 
Scientific and the Communication units, to the specific needs 
of different types of publications; and (2) incorporate those 
workflows into the Guide to producing EMCDDA scientific 
publications (and formally adopt such Guide).      
In view of the short time available at the end of 2018, it was not 
possible to provide the IAS with a reply to this advance draft 
audit report. This answer was provided in January 2019. The 
action plan aimed at dealing with these IAS recommendations 
will be issued only after the final audit report is issued.      
In late October, the IAS conducted a fact-finding mission on 
the potential internal control weaknesses in the agency, an 
initiative triggered by some issues related to human resources 
management that were reported to the IAS by the European 
Anti-Fraud Office (OLAF). The results of that mission, first 
delivered at the end of 2018, did not lead to any findings that 
would even remotely relate to fraud. A number of issues and 
recommendations have, nevertheless, been raised by the IAS; 
a summary of these is provided below:
   With a view to promoting transparency and enhancing 
controls in recruitment procedures, the EMCDDA should 
consider revising its current guidelines, in order to provide 
further clarification on the meaning of potential conflicts 
of interest.
  Internal controls in the area of staff selection/recruitment, 
aimed at ensuring full alignment with applicable rules, 
should be reinforced. Moreover, the IT application used 
in calculating the eligibility of minimum work experience 
requirements should be updated.
  With a view to mitigating risks of non-compliance with 
the regulations in force, the EMCDDA should request 
technical advice from the EC on how to revise the method 
for the calculation and allocation of ‘priority points’ in the 
framework of promotion/reclassification procedures.   
Early in 2019, the EMCDDA declared its willingness to endorse 
these IAS recommendations.
I European Court of Auditors
In 2018, the EMCDDA followed up on the recommendations 
expressed by the European Court of Auditors. This is outlined 
below.
The EMCDDA Director has become the direct hierarchical 
superior and reporting manager of the EMCDDA Accounting 
Officer and Deputy Accounting Officer, in particular in order 
to be able to carry out the annual appraisal of the latter. This 
measure has been taken by taking into account the size 
and the organisational structure of the EMCDDA and by 
considering the fact that the independence of the EMCDDA 
accounting officers has been consistently ensured in the past, 
in accordance with the relevant rules, in particular via the 
appointment of these officers by the EMCDDA Management 
Board, via the functional reporting and accountability of these 
officers to the latter and via the diligent application of the rules 
on the segregation of the duties of the different EMCDDA 
financial actors. 
At the end of 2018, the EMCDDA concluded its announced 
assessment of the estimated costs and benefits of the 
publication of external selection/vacancy notices via the 
European Personnel Selection Office (EPSO) website (on 
top of the publication operated via the dissemination to the 
members of its governing bodies, the Reitox NFPs and the 
Inter- Agency Job-Advertisement Portal, the online shared 
platform developed by the network of EU agencies). By 
considering that this publication required (at that point in 
time) the translation of the vacancy notice into all EU official 
languages, this assessment indicated that this publication 
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would entail significant additional cost and would substantially 
increase the duration of the recruitment procedures, despite 
of the further standardisation and streamlining of the template 
to be used for future EMCDDA vacancy notices (in order to 
reduce as much as possible translation costs).
On 21 January 2019, EPSO informed the EU agencies about 
its decision to change and simplify the procedure and the 
conditions required for the publication of vacancy notices on 
the EPSO website (in particular this publication will simply 
require the translation into all EU official languages of just 
the relevant job title). As a result the EMCDDA will publish all 
selection/vacancy notices also via the EPSO website, without 
prejudice to the necessary publication of these notices on its 
website.
In accordance with the relevant EU legal framework governing 
‘e-procurement’ procedures, and the timetable established 
in this context for the rollout of e-procurement in the EU, the 
EMCDDA has duly completed the operations required to be 
able to use ‘e-tendering’ and ‘e-submission’ from October 
2018. This completed the measures that have been taken 
since August 2015 to set up, in cooperation with the relevant 
EC services, the technical configuration/ICT tool required for 
‘e-invoicing’.
I Follow-up on observations from the  discharge authority
I Measures taken in light of the observations and  comments that accompanied the decision on   discharge for 2016
Observation No 1 of EP discharge decision
Notes that, according to the Court’s report, in 2012 the 
Centre signed a framework contract with a maximum amount 
for signing specific contracts of EUR 250 000, which was 
specified in the contract notice; notes with concern that the 
Centre did not respect this ceiling; notes moreover that by 
the end of 2015 the total payments made under this contract 
amounted to EUR 382 181, i.e. exceeded it by 50%; points out 
that the payments made above the ceiling indicate that the 
Centre’s procedure for monitoring framework contracts should 
be improved; calls on the Centre to report to the discharge 
authority on the status of the corrective action which is 
currently marked as ‘ongoing’ and on the future improvements 
in the monitoring of framework contracts.
Measures taken by the EMCDDA
In line with the relevant financial rules, the above-mentioned 
amount was indeed given as an estimate in the contract 
notice published for the purpose of the procurement at stake. 
The framework contract that was concluded pursuant to this 
process neither mentioned this amount nor referred to any 
maximum threshold.
That being said, the EMCDDA has terminated the execution of 
this contract and set up a new procurement process for the 
services concerned. Furthermore, it has put in place a specific 
process to improve the central planning and monitoring of 
its procurements (an annual procurement plan), with special 
attention given to framework contracts.
Observation No 2 of EP discharge decision
Notes that, according to the Court’s report, for two framework 
contracts, with maximum values of EUR 135 000 and EUR 
650 000, one of the Centre’s employees acted as authorising 
officer by delegation when appointing the evaluation 
committee, taking the award decisions and signing the 
contracts; notes, however, that the delegation granted by the 
authorising officer was limited to EUR 130 000 and did not 
explicitly refer to framework contracts; notes that, according to 
the Centre’s reply, the maximum values of the two framework 
contracts indicated the total cumulative amount of the 
specific contracts likely to be concluded for their execution; 
notes with satisfaction that the Centre will adjust its decision 
on the delegation of the authorising officer’s powers in order to 
set out more explicitly the acts covered by this delegation.
Measures taken by the EMCDDA
Since 2017, the EMCDDA has duly implemented the 
announced follow-up measures as required to further clarify 
the terms and scope of the delegation of the powers of the 
EMCDDA authorising officer, in particular by ensuring a more 
explicit indication of the acts covered by this delegation, 
with special attention given to the operations concerning 
procurements and framework contracts.
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Observation No 6 of EP discharge decision
Notes that the Centre put in place a new procurement plan 
which was successfully executed in close collaboration with all 
units; calls on the Centre to report to the discharge authority 
on the implementation of this plan.
Measures taken by the EMCDDA
Since 2016, the EMCDDA has put in place and implemented 
a specific procedure (an annual procurement plan and 
specific periodical progress reporting) to enhance the central 
planning and monitoring of its procurements, with special 
attention given to framework contracts within the limit of their 
established maximum threshold.
Observation No 11 of EP discharge decision
Appreciates that the Centre already adopted a policy on 
protecting dignity of the person and preventing harassment; 
invites the Centre to organise training sessions in order to 
increase the awareness of staff.     
Measures taken by the EMCDDA
Specific information and training have been provided at the 
moment of the adoption of the policy referred to for EMCDDA 
staff and for confidential counsellors appointed for the 
implementation of this policy. Furthermore, EMCDDA staff 
are going to participate in the initiatives/actions organised by 
EIGE to improve the prevention and handling of harassment 
within EU Agencies (in particular, in 2018, workshops were 
run on sexual harassment for confidential counsellors, human 
resource officers, and middle and top management).
Observation No 13 of EP discharge decision
Notes that the declaration of interest of the director of the 
Centre is published on the Centre’s website; calls on the 
Centre to make more declarations of interest public on its 
website.    
Measures taken by the EMCDDA
The EMCDDA has published on its website the declarations 
of interest of the members of its Management Board and 
Scientific Committee.
Observation No 15 of EP discharge decision
Expresses the need to establish an independent disclosure, 
advice and referral body with sufficient budgetary resources, 
in order to help whistle-blowers use the right channels to 
disclose their information on possible irregularities affecting 
the financial interests of the Union, while protecting their 
confidentiality and offering needed support and advice.  
Measures taken by the EMCDDA
The EMCDDA internal procedures and guidelines on 
whistleblowing provide for specific protection for whistle-
blowers, in particular limiting the burden of proof, protecting 
the confidentiality of their identity, ensuring mobility to 
safeguard them against hostile reactions, ensuring that they 
do not suffer adverse consequences in the appraisal and 
promotion/reclassification process, and applying disciplinary 
measures for any form of retaliation against whistle-blowers. 
Furthermore, these procedures/guidelines provide for 
confidential and impartial guidance, advice and support to 
potential whistle-blowers via the EMCDDA human resources 
management service (concerning, for instance, the reporting 
channel that may be best used, the alternative procedures 
available if the information concerned does not qualify for 
whistleblowing, and the protective measures that may apply). 
Finally, the web-based Fraud Notification System of OLAF 
gives potential whistle-blowers the opportunity to enter into 
a dialogue with OLAF investigators, allowing verification of 
whether or not the information in their possession falls within 
the remit of OLAF.
Observation No 17 of EP discharge decision
Notes with concern that, according to the Court’s report, in 
its audit report of January 2016, the Commission’s Internal 
Audit Service (IAS) highlighted a strong need to improve 
the Centre’s management of IT projects; notes with concern 
further that the IAS concluded in particular that there is no 
overarching long-term strategic vision for the IT systems 
supporting the Centre’s core operational processes, that 
its IT project management methodology was only partially 
adapted to its needs and that the process to manage system 
requirements is inadequate; notes that the Centre and the IAS 
agreed on a plan to take corrective action; calls on the Centre 
to report to the discharge authority on the progress made. 
Measures taken by the EMCDDA
The following actions have been implemented, taking into 
account the size of the EMCDDA and the resources that it can 
mobilise: 
  In January 2018, the design and adoption of the 2025 ICT 
multi-annual strategy has been accomplished and the 
recommendations were promptly closed by the IAS. 
  In early 2018, the first version of the EMCDDA Enterprise 
Architecture Management Framework was issued. 
Following the planned next steps, the final adoption of this 
Framework was expected in December 2018. 
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  During the past two years, the EMCDDA had in place a 
project management approach based on the PRINCE 
PM methodology. The EMCDDA has opted to move to 
PM2 methodology (applied in the EC), since the latter is 
deemed as a better fit to its core business needs. The aim 
is to fully implement this methodology by the end of 2018. 
  Significant progress is expected to be seen in the 
implementation of the final two IAS recommendations, 
namely concerning the definition of adequate 
requirements in the management process And system 
development methodology, by the end of 2018. 
Observation No 18 of EP discharge decision
Notes that along the lines set up in its 2016-18 Strategic 
Internal Audit Plan, the IAS carried out, in September 2016, a 
‘Limited Review on Business Continuity in the EMCDDA’; notes 
that a related draft report yielded three recommendations 
rated by the internal auditor as ‘important’, covering issues 
on business impact analysis, training and awareness-raising 
actions, and the list of critical records; notes that an action 
plan aimed at dealing with the three recommendations will 
be elaborated following receipt of the final report on business 
continuity in the Centre; calls on the Centre to report to the 
discharge authority on the implementation of this action plan.
Measures taken by the EMCDDA
The follow-up measures required by the above-mentioned 
recommendations were duly and timely implemented in 2017, 
as planned.
Observation No 19 of EP discharge decision
Encourages the commitment of the Centre to provide 
improved access to its data to interested third parties, given 
that one of its main objectives is the dissemination of data 
and information on the state of the drugs problem, including 
data on relevant new trends; expects such a commitment to 
result in effective corresponding actions being taken.
Measures taken by the EMCDDA
The EMCDDA website is the favoured vehicle for dissemination, 
with more than 1 million visitors in 2017. In this context, for the 
first time, 30 Country Drug Reports complemented the 2017 
European Drug Report, by providing an overview of national 
drug situations (in the EU-28, Turkey and Norway).
The EMCDDA’s BPP was revamped for the launch of the Health 
and social responses to drug problems: a European guide and 
to make it more practice-oriented through the addition of new 
elements (the online registry of evidence-based prevention 
programmes — Xchange; the evidence database, including 
systematic reviews and regular updates; the Healthy Nightlife 
Toolbox; and the policy and practice briefings).
The EMCDDA’s online presence was also developed through 
social media activities and the EMCDDA gained around 2 000 
new followers on each of its two main channels, namely Twitter 
and Facebook. In 2017, the EMCDDA established an additional 
social media account on Instagram. Videos published by the 
EMCDDA on YouTube received around 190 000 views during 
2017 (twice as many as in 2016). Furthermore, 49 digital 
campaigns were launched, resulting in over 83 000 individual 
emails being sent to subscribers.
In 2017, the EMCDDA produced 40 news outputs on its 
website (i.e. 18 news releases, 12 fact sheets and 10 web 
news items). Social media messages were proposed for all 
packages. Promotional initiatives were organised for the 
launch of the European Drug Report 2017 (a brochure, adverts 
and specialised newsletter slots) and the Health and social 
responses to drug problems: a European guide, including 
media relations events. Four editions of the EMCDDA 
newsletter were produced (including two special issues 
focusing on the EDR and the Health and social responses to 
drug problems: a European guide). Promotional activities were 
carried out via specialised drug news services. Key websites 
were targeted by sending them alerts to the EMCDDA’s 
products (i.e. the EU bookshop and the EU health portal). 
Displays were mounted at key conferences. A communication 
plan was drawn up for the EMCDDA’s chairmanship of the 
network of the EU agencies in the area of JHA. Finally, a 
promotional brochure and web page that were dedicated 
to this initiative were published and a range of promotional 
initiatives were organised (an EP magazine advert and web 
banners).
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 CHAPTER 3
 External evaluation
In line with Article 23 of the EMCDDA Founding Regulation 
recast, the EC shall initiate an external evaluation of the 
agency every six years and forward the evaluation report to the 
EP, the Council and the Management Board of the EMCDDA. 
The fourth external evaluation of the EMCDDA was carried out 
by the EC in 2018 with support from an external consultant. 
The final report of the external contractor, which was presented 
by the EC at the Management Board meeting in December, 
contained some very positive results for the EMCDDA. 
According to the report, the agency is performing very well, 
delivers excellent outputs and has a high reputation at the 
European and international levels. 
Some recommendations for improvements were put forward 
by the consultants, in particular concerning a number of issues 
that could be implemented within the current legal framework, 
such as improvements to the dissemination of EMCDDA 
outputs, human resources management and activity-based 
management. 
Some of the other recommendations focused on different 
aspects, such as enhancing the EMCDDA’s capacity to monitor 
drug supply-side issues, focusing international cooperation 
activities on adding value to EMCDDA core objectives and 
broadening the scope of the mandate to other types of 
addictions.
The Commission report, which presents the main conclusions 
of the evaluation, was prepared by the EC and adopted on 14 
May 2019. 
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 CHAPTER 4
  Assessment of the effectiveness of the 
internal control systems
I  Risk management and compliance with, and effectiveness of, the internal control standards
As in previous years, a comprehensive risk identification and 
assessment exercise aimed at improving risk management in 
the EMCDDA was carried out in 2018. The central risk register 
was regularly updated. This register identifies, for each area, 
the estimated risk level, impact and response, the mitigating 
measures currently in place and the list of programmes, 
projects and actions that will contribute to the reduction 
of the outstanding residual risk levels. As mentioned in the 
section in Chapter 2 entitled ‘Assessment of audit results’, risk 
assessment was an exercise that was carried out continuously 
at the EMCDDA throughout the year, while a comprehensive 
analysis was performed by the managers in the context of the 
preparation of the PDs. 
A comprehensive document that reviews and sets out the 
progress made in the implementation of the EMCDDA’s 
internal control standards was drawn up in early 2013. This 
document has been regularly updated since then, up to (and 
including) 2018.
Following a Management Board decision taken in December 
2017, a new Internal Control Framework (ICF) applicable to 
the EMCDDA was adopted. This new ICF is fully consistent 
with the EC standards, internal control principles and relevant 
guidelines. A document with a full repository of the state of 
play of implementation of the 17 ICF principles was drafted 
throughout 2018 and it was near completion in December 
2018. (The final steps required an analysis of a number of 
important pieces of information, such as the preliminary 
results of the IAS fact-finding mission on internal control 
weaknesses, the conclusions emerging from the external 
evaluation and the results obtained under the survey of 
EMCDDA staff engagement; all of these arrived in either 
late November or mid-December 2018). The year 2018 was 
therefore a transition year as regards the monitoring of the 
agency’s compliance with internal control standards and 
principles.
The EMCDDA’s business continuity plan reached maturity in 
2018 after completing the set-up of the back-up facilities in 
Madrid for the purposes of disaster recoveries. For this reason, 
the residual risks relating to business continuity have been 
downgraded to low and therefore have been taken out of the 
central risk register.    
Clear progress has also been made regarding the 
implementation of measures aimed at improving project 
management in the EMCDDA, particularly in the ICT sector.
The monitoring of performance, supported by KPIs, was further 
consolidated throughout 2018, building on the achievements 
of previous years. This was the fourth year in which KPIs 
were in place for all of the main areas of work in the annual 
work programme; the agency has continued developing the 
necessary data-collection and reporting mechanisms, has 
piloted some new measurement tools, has refined working 
definitions and has developed an internal monitoring and 
evaluation plan. 
The performance model has evolved to reflect the current 
strategic direction and organisational needs set out in the 
EMCDDA Strategy 2025, as well as developments concerning 
the performance models implemented by other EU Agencies. 
As a result, the agency’s performance model is changing 
from a model that included a high number of KPIs (i.e. 50 
KPIs in 2018) to a model with a limited number of composite 
KPIs (i.e. 10 KPIs), that is, KPIs built on and measured by 
sets of underlying lower level performance indicators. This 
new performance model has already been presented in the 
EMCDDA PD 2019-21 (Consultation draft), as submitted to 
the EC for formal opinion on 31 January 2018. The final draft 
of this PD 2019-21 was submitted on 28 November to the 
EMCDDA Management Board and was adopted at the Board 
meeting on 13 December 2018. It became applicable on  
1 January 2019.
Moreover, the agency has been working on the development of 
an IT tool to integrate the planning and monitoring of activities 
(MATRIX). The progress achieved in this area has been slower 
than originally planned because of several factors: (1) the 
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need to prioritise work on the PD (the top-level priority) from 
the perspective of the business owner (the planning function) 
and (2) the development needs of other top priority (level 1) 
projects from the perspective of the ICT team, in particular 
relating to project management automation processes. 
Customisation of MATRIX started in 2018. It is expected 
that the results of the ensuing piloting phase will allow 
management to make a decision on whether or not to adopt 
this monitoring tool.
Internal EMCDDA coordination mechanisms (e.g. the Heads of 
unit meetings, Editorial board meetings, Product Coordinating 
Meetings, ICT Steering Committee meetings and the Scientific 
coordination meetings) contributed to strengthening risk 
management processes, by enhancing the capacity of 
managers and other key staff to closely monitor all major 
issues related to the timely and effective implementation of 
planned activities, the delivery of outputs and the achievement 
of results. 
The following factors are worth mentioning as regards the 
materialisation of risks to the performance of the EMCDDA’s 
activities and consequently to the agency’s capability to reach 
its core objectives.
The nominal value of the EU subsidy to the EMCDDA for 
2018 was EUR 105 000 lower than for 2013. Whether the EU 
subsidy can be maintained around the 2013 level represents, 
in itself, a medium- to high-level risk to the agency, owing to 
the serious erosion of its value in real terms if the subsidy 
drops below this level, as well as the increasing financial needs 
of the agency. The increase in 2018 of the weighting factor 
applicable to staff remunerations and the looming end (in 
2020) of building rental discounts, which was obtained in early 
2016, may render this risk even more serious. 
Risks related to the implementation of operational activities 
materialised once again in 2018. This concerns in particular 
the lack of proper funding for certain Reitox NFPs which has 
been apparent since 2014, with a peak in 2016 and 2017. In 
particular, funding cuts made by national authorities to some 
NFPs’ budgets in the last quarter of 2016 (cuts that were 
maintained in 2017) may imply future reductions in co-funding 
provided by the EMCDDA. This situation improved somewhat 
in 2018, as certain Member States maintained or increased 
their financial contributions to their NFPs. Nevertheless, the 
current situation could trigger further negative consequences 
for the capabilities of the NFPs with regard to complying with 
their reporting obligations. In addition, these difficulties have 
been compounded by lingering budget constraints faced 
by the EMCDDA itself, which have led to decreases in the 
amounts it grants to NFPs. 
Therefore, the rationalisation of the present NFP reporting 
package needed to be carried out and this must continue; this 
involves, notably, regular reviews of the availability of core data 
needs, on the basis of properly defined priorities; providing 
feedback to the NFPs on their performance in respect of 
the availability of core data and their reporting obligations 
towards the EMCDDA; and enhancement of coordination and 
performance monitoring. 
Furthermore, reductions in the reporting capacities of Member 
States have been evident since 2015. The initial consequence 
of this is that the timeliness and comprehensiveness 
of Member States’ reporting on new threats and drug 
developments have been affected; moreover, some 
comparative data became unavailable, which curtailed the 
possibility of carrying out useful analyses at the European level. 
Following the materialisation of this risk, it became clear 
that closer monitoring of and the provision of more feedback 
to the Member States on their reporting performance was 
envisaged and is currently ongoing. In addition, an assessment 
of the implementation of the key epidemiological indicators 
in the Members States takes place every three years and the 
NFPs are provided with the necessary feedback. Additionally, 
evaluation of the reporting capacity of MS could be included 
in forthcoming systemic reviews. Last but not least, closer 
attention ought to be paid to reporting biases and statistical 
approaches; these measures should allow corrective action to 
be taken by those Member States chiefly affected.
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 CHAPTER 5
  Management assurance
I  Declaration of assurance by the Authorising Officer
I, the undersigned, Director of the European Monitoring Centre for Drugs and Drug Addiction
In my capacity as Authorising Officer
  Declare that the information contained in this report gives a true and fair view (9).
  State that I have reasonable assurance that the resources assigned to the activities 
described in this report have been used for their intended purpose and in accordance with 
the principles of sound financial management, and that the control procedures put in place 
give the necessary guarantees concerning the legality and regularity of the underlying 
transactions.
  This reasonable assurance is based on my own judgement and on the information at my 
disposal, such as the results of the self-assessment, the observations of the Internal Audit 
Service, the implementation of recommendations issued under ex post assessments and 
the lessons learnt from the reports of the Court of Auditors for years prior to the year of this 
declaration.
  Confirm that I am not aware of anything not reported here that could harm the interests of 
the institution.
Done in Lisbon on 20 May 2019
Alexis Goosdeel 
Director
 
(9) ‘True and fair’ in this context means a reliable, complete and correct view on the state of affairs in the service. 
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I  Annex 1 Organisational chart
Director
Alexis Goosdeel (DIR)
Unit
Public health
(HEA) 
Unit
Risks to public 
safety and security
(SAS)
Unit
Reitox and
external partners 
(RTX)
Unit
Communication
(COM)
Unit
Information and
communication
technology
(ICT)
Unit
Resources 
management and
administrative 
services
(ADM)
Sector
Support to policy
Sector
Trends and analysis
Sector
Support to practice
Sector
Infrastructure and
logistics
Sector
Financial management
Sector
Human resources
management
Sector
Markets, crime and
supply reduction
Sector
International cooperation
Sector
Media relations
and marketing
Sector
Service delivery
Sector
Action on new drugs
Executive oce (EXO) 
Data Protection Ocer (DPO)
Scientic division (SDI)
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I  Annex 2 Staff details
I Breakdown of EMCDDA staff as of  31 December 2018
Categories/grade Officials
Gender Temporary 
agent
Gender
Male Female Male Female
AD
15
14 1 1
13 1 1 3 2 1
12 3 3 5 4 1
11 6 2 4
10 2 1 1
9 2 2 10 4 6
8 7 2 5
7 7 3 4
6
5 2 2
Subtotal AD 6 6 0 43 21 22
AST
11 1 1
10
9 3 2 1
8 1 1 2 2
7 3 1 2
6 7 3 4
5 1 1 4 2 2
4 1 1
3 1 1
2
1
Subtotal AST 3 0 3 21 11 10
TOTAL 9 6 3 64 32 32
Function group
Gender
Male Female
CA
IV 4 1 4
III 9 3 6
II 13 1 11
I 3 3
TOTAL CA 29 8 21
AD: administrator; AST: assistant; CA: contract agent.
Total EMCDDA 
staff
Gender
Male Female
102 46 56
% 45% 55%
Seconded 
national expert
1 0
Annexes
General Report of Activities 2018
74 / 87
Annexes
I Results of the 2018 benchmarking exercise
Job type (sub-)category % of staff
Administrative support and coordination 17.53
Administrative support 17.06
Coordination 0.47
Operational 72.95
Top level operational coordination 4.06
Programme management and 
implementation
57.50
Evaluation and impact assessment 0.00
general operational 11.39
Neutral 9.52
Finance/control 9.52
linguistics 0,00
0 5 10 15 20 25 30 35
United Kingdom
Sweden
Finland
Slovakia
Slovenia
Romania
Portugal
Poland
Austria
Netherlands
Malta
Hungary
Luxembourg
Lithuania
Latvia
Cyprus
Italy
France
Spain
Greece
Ireland
Estonia
Germany
Denmark
Czechia
Croatia
Bulgaria
Belgium
Ocials (9) Temporary agents (64) Contract agents (29)
Function group 
and grade
Number of 
days
Function group 
and grade
Number of 
days 
AD5 12 AST9 0
AD6 0 AST10 0
AD7 37.5 AST11 0
AD8 44.5 GFI1 0
AD9 47.5 GFI2 0
AD10 12.5 GFI3 10.5
AD11 39 GFII4 4
AD12 5.5 GFII5 8
AD13 0 GFII6 19.5
AD14 0 GFII7 32.5
AD15 0 GFIII8 0
AD16 0 GFIII9 28.5
AST1 0 GFIII10 4.5
AST2 0 GFIII11 14.5
AST3 0 GFIII12 3
AST4 1 GFIV13 6
AST5 27.5 GFIV14 10.5
AST6 42 GFIV15 1. 5
AST7 15.5 GFIV16 15
AST8 27 GFIV17
Total: 469.5
I Staff by nationality
I Number of days of leave authorised under   the flexitime and compensatory leave schemes 
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I  Annex 3 Implementation of the 2018 work programme by objectives and  expected outputs/results
This annex presents in detail the activities contained within the work programme for 2018 and 
how they were carried out during the course of the year. It is available online. 
I  Annex 4 Key performance indicators 
This annex is available online. 
I  Annex 5 Key external events, conferences and meetings 
This annex is available online. 
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I  Annex 6 Members of the EMCDDA’s statutory bodies
I Management Board
The Management Board consists of one representative from each Member State, two representatives of the EC, two independent 
experts who are particularly knowledgeable in the field of drugs (designated by the EP) and one representative from each 
country that has concluded an agreement with the EMCDDA (i.e. Norway and Turkey). Non-voting observers, such as those from 
international organisations with which the agency cooperates, may also be invited to Management Board meetings.
Country/organisation Member Substitute
Belgium Claude gIllARD Vladimir MARTENS
Bulgaria Plamen POPOV Momtchil VASSIlEV
Czechia Jamila VEDRAlOVÁ lucia KISSOVA
Denmark lars PETERSEN Sofie DENCKER
Germany Marlene MORTlER Jörg PIETSCH
Estonia Tiina DREll Ain PEIl
Ireland Jim WAlSH brian DOWlINg
Greece Christina DIAMANTOPOUlOU gerasimos PAPANASTASATOS
Spain María Azucena MARTÍ PAlACIOS Elena AlAVAREZ MARTÍN
France laura d’ARRIgO (Chair) Nicolas PRISSE
Croatia Željko PETKOVIĆ Sanja MIKUlIĆ
Italy Maria CONTENTO Elisabetta SIMEONI
Cyprus Stelios SERgIDES Maria AFXENTIOU
Latvia Dzintars MOZgIS
Lithuania Inga JUOZAPAVIČIENÉ gražina bElIAN
Luxembourg Xavier POOS Alain ORIgER
Hungary Mónika SZÁSZIK Ibolya CSÁKÓ
Malta Richard MUSCAT Marilyn ClARK
Netherlands Victor SANNES
Austria Franz PIETSCH (Vice-Chair) Raphael bAYER
Poland Piotr JAbŁOŃSKI bogusława bUKOWSKA
Portugal João gOUlÃO Manuel CARDOSO
Romania Constantin NEgOIŢĂ Ruxanda IlIESCU
Slovenia Vesna-Kerstin PETRIČ Jože HREN
Slovakia Nadežda lObODÁŠOVÁ Eva DEbNÁROVÁ
Finland Elina KOTOVIRTA Kari PAASO
Sweden Johan CARlSON Henrik MElIN
United Kingdom Rosanna O’CONNOR lauren COMbER
European Commission Paraskevi MICHOU and Olivier ONIDI 
laurent MUSCHEl and Floriana SIPAlA  
or Wojciech KAŁAMARZ
European Parliament Wolfgang gÖTZ and Tomas ZAbRANSKY
Norwegian representatives lilly Sofie OTTESEN Hege Christina bREDESEN
Turkish representatives İbRAHIM H. SEYDIOĞUllARI Murat SARIgÜZEl
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Scientific Committee Anne line bRETTEVIllE-JENSEN
Reitox spokesperson lies gREMEAUX
UNODC gilberto gERRA
Council of Europe Pompidou Group Thomas KATTAU
WHO Carina FERREIRA bORgES
I Executive Committee
The Management Board is assisted by an Executive Committee. The Executive Committee is 
made up of the Chair and the Vice-Chair of the Management Board, two other members of the 
Management Board representing the Member States and appointed by the Management Board, and 
two representatives of the EC. The Executive Committee prepares and follows up the decisions of the 
Management Board and assists and advises the EMCDDA Director.
Laura d’ARRIGO France (Chair of the Management board)
Franz PIETSCH Austria (Vice-Chair of the Management board)
Xavier POOS luxembourg
João GOULÃO Portugal
Claude GILLARD belgium (Chair of the budget Committee, observer)
Two representatives of the European Commission
I Scientific Committee
The members of this Committee are selected for their independence and proven expertise in a 
particular field/speciality, as indicated below.
Field/speciality Scientific Committee Member(s)
Basic biological, neurobiological and behavioural research
Fernando RODRIgUEZ de FONSECA
Rainer SPANAgEl
Drug policy
Henri bERgERON
Anne line bRETTEVIllE-JENSEN
Krzysztof KRAJEWSKI
Population-based research
Catherine COMISKEY
Paul DARgAN
Dirk J. KORF
Matthew HICKMAN
Supply, supply reduction letizia PAOlI
Demand reduction
gerhard bÜHRINgER
Marina DAVOlI
Fabrizio FAggIANO
gabriele FISCHER
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I Economic outturn account
Economic outturn account 2018 2017 Variation
Contributions of EFTA countries belonging to the EEA 412 932.41 403 487.34 9 445.07
Recovery of expenses 34 399.08 16 953.19 17 445.89
Revenues from administrative operations 276 550.49 265 543.74 11 006.75
Other operating revenue 15 591 436.84 15 305 558.97 285 877.87
Total operating revenue 16 315 318.82 15 991 543.24 323 775.58
Administrative expenses -12 892 148.92 -12 108 992.97 783 155.95
All staff expenses -10 343 817.11 -9 512 006.18 831 810.93
Fixed asset related expenses -274 773.02 -271 372.3 3 400.72
Other administrative expenses -2 273 558.79 -2 325 614.49 -52 055.7
Operational expenses -4 187 441.16 -4 458 218.17 -270 777.01
Other operational expenses -4 187 441.16 -4 458 218.17 -270 777.01
Total operating expenses -17 079 590.08 -16 567 211.14 -512 378.94
Surplus/(deficit) from operating activities -764 271.26 -575 667.9 -188 603.36
Financial revenues 0.66 1 757.43 -1 756.77
Financial expenses -4 713.78 -3 679.85 -1 033.93
Surplus/(deficit) from non-operating activities -4 713.12 -1 922.42 -2 790.7
Surplus/(deficit) from ordinary activities -768 984.38 -577 590.32 191 394.06
Economic outturn for the year -768 984.38 -577 590.32 191 394.06
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I EMCDDA 2018 budget execution by nature of expenditure
Title Description EUR
1.
Expenditure relating to persons working with the EMCDDA  
Staff in active employment 10 414 513.30
Other staff-related expenditure (exchange of officials, etc.) 0.00
Total under Title 1 10 414 513.30
2.
Expenditure for support activities
Investment in immovable property, rental of buildings and associated costs 624 258.38
Data processing 564 918.61
Movable property and associated costs 104 227.36
Current administrative expenditure + postal charges and telecommunications 80 800.54
Socio-medical infrastructure 20 311.95
Total under Title 2 1 394 516.84
3.
Expenditure for operational activities
Statutory meetings 184 479.14
Expenditure on formal and other meetings + representatives' expenses 462 674.52
Studies, surveys, consultations 749 232.92
Publishing and translations 551 482.41
European Network on Drugs and Drug Addiction Reitox 2 088 495.58
Missions 314 304.77
Total under Title 3 — Section 1.01 4 350 669.34
Section 1.02 — Total core budget 16 159 699.48
Section 1.03
4.
Expenditure relating to other subsidies
EU financing of specific projects 
4a. IPA 6: financing for implementing pre-accession strategy 266 467.41
5. Other expenses (reserve) 0.00
Total budget 16 426 166.89
Notes:
A. The amounts encompass (1) budget appropriations for the current year (C1)and (2) appropriations resulting from internal assigned revenue incurred in 
2018 (C4).
B. The amounts committed under Title 4a contain the commitment appropriations, carried forward from the previous year. Project IPA 6 is still ongoing.
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I Execution of the budget: credit consumption, 2018
Commitment appropriations
Title Description Fund source % consumption of available credits
1. Staff C1 100
2. Expenditure for support activities C1 100
3. Expenditure for operational activities C1 99.94
4a. Expenditure relating to IPA 5 R0 -
4b. Expenditure relating to IPA 6 R0 91.17
Total consumption of core budget (Titles 1, 2, 3 ) 99.98
I Balance sheet: assets
Assets 31.12.2018 31.12.2017 Variation
A. Non-current assets
Intangible assets 435 941.94 397 171.18 38 770.76
Property, plant and equipment 452 572.55 344 666.32 107 906.23
Plant and equipment 97 460.74 89 046.55 8 414.19
Computer hardware 317 295.55 190 551.28 126 744.27
Furniture and vehicles 37 816.26 65 068.49 -27 252.23
Long term pre-financing 114 022.25 576 636.04 -462 613.79
Total non-current assets 1 002 536.74 1 318 473.54 -315 936.8
B. Current assets
Short-term pre-financing 469 486.13 726 888.96 -257 402.83
Short-term receivables 436 020.23 308 460.93 127 559.30
Current receivables 199 743.89 121 239.53 78 504.36
Other 236 276.34 187 221.40 49 054.94
Accrued income -2 920.55 2 920.55
Deferred charges 236 276.34 190 141.95 46 134.39
Cash and cash equivalents 723 896.86 1 533 369.27 -809 472.41
Total current assents 1 629 403.22 2 568 719.16 -939 315.94
Total 2 631 939.96 3 887 192.70 -1 255 252.74
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I Balance sheet: liabilities
Liabilities 31.12.2018 31.12.2017 Variation
Liabilities
Net assets 1 648 947.42 2 417 931.80 -768 984,38
Accumulated surplus/deficit 2 417 931.80 2 995 522.12 -577 590.32
Economic outturn for the year — profit+/loss- -768 984.38 -577 590.32 -191 394.06
Total net assets 1 648 947.42 2 417 931.80 -768 984.38
Current liabilities
Current liabilities — accounts payable
Current payables 64 943,81 6 007.66 58 936,15
Sundry payables 398.40 -398,40
Other 823 051,45 1 023 871.44 -200 819,99
Accrued charges 821 223,98 1 014 038.15 -192 814,17
Deferred income 1 827,47 9 833.29 -8 005,82
Accounts payable with consolidated EU entities 94 997,28 438 983.40 -343 986,12
Pre-financing received from consolidated EU entities 94 997,28 438 983.40 -343 986,12
Other accounts payable against consolidated EU entities
Total current liabilities 982 992.54 1 469 260.90 -486 268.36
Total 2 631 939.96 3 887 192.70 -1 255 252.74
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I Budget outturn account for the financial year 2018
Budget outturn account 2018 2017
Revenue
balancing EC subsidy + 15 445 600.00 15 135 600.00
Other subsidy from EC (IPA 6) + 340 000.00
Fee income +
Other income (Norway contribution + Turkey contributuon + C4 internal assigned revenues +  bank 
interests amending budget Nos 1 and 2)
+ 723 882.64 693 197.96
Total revenue (a) 16 169 482.64 16 168 797.96
Expenditure
Title I: Staff
Payments - 10 445 666.13 9 809 524.44
Appropriations carried over - 58 870.35 157 526.19
Title II: Administrative Expenses
Payments - 1 102 888.05 1 005 724.32
Appropriations carried over - 300 736.67 607 904.28
Title III: Operating Expenditure 
Payments - 4 461 067.47 4 555 075.39
Appropriations carried over - 95 545.65 203 511.55
Total expenditure (b) 16 464 774.32 16 339 266.17
Outturn for the financial year (a-b) -295 291.68 -170 468.21
Cancellation of unused payment appropriations carried over from previous year (C8 title 1 & 2) + 27 093.70 18 245.88
Adjustment for carry-over from the previous year of appropriations available at 31.12 arising from 
assigned revenue
+ 322 278.86 380 860.06
Exchange differences for the year (gain +/loss -) +/- -1 911.27 -271.84
Cancellation of unused payment appropriations  IPA 5-Final balance reimbursed to the EC Dg NEAR -28 768.80 -28 768.80
Norway prorata 2018 -722.89 -6 194.39
Turkey prorata 2018 -426.63 -3 638.90
bAlANCE OF THE OUTTURN ACCOUNT FOR THE FINANCIAl YEAR 22 251.29 189 763.80
Balance of the outturn account for the financial year 189 763.80 215 188.58
balance year N-1 +/- 189 763.80 215 188.58
Positive balance from year N-1 reimbursed in year N to the Commission - -189 763.80 -215 188.58
Result used for determining amounts in general accounting 22 251.29 189 763.80
Commission subsidy — agency registers accrued revenue and Commission accrued expense 15 423 348.71
Pre-financing remaining open to be reimbursed by agency to Commission in year N+1 22 251.29
Not included in the budget outturn:
Interest generated by 31/12/N on the EC balancing subsidy funds and to be reimbursed to the EC (liability) (+)
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About this report
The General Report of Activities is an annual publication providing a detailed progress 
report of the EMCDDA’s activities over a 12-month period. It catalogues the Centre’s 
achievements in each area of its annual work programme. The report is a useful information 
source for all those seeking comprehensive information on the Centre and its work.
About the EMCDDA
The European Monitoring Centre for Drugs and Drug Addiction is the hub of drug-related 
information in Europe. Its mission is to provide the European Union and its Member States 
with ‘factual, objective, reliable and comparable information’ on drugs and drug addiction 
and their consequences. Established in 1993, it opened its doors in Lisbon in 1995,  
and is one of the European Union’s decentralised agencies. The Centre offers policymakers 
the evidence base they need for drawing up drug laws and strategies. It also helps 
professionals and researchers pinpoint best practice and new areas for analysis.
